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The Society for Vascular Surgery (SVS) and the American Venous Forum (AVF) have developed clinical practice
guidelines for the care of patients with varicose veins of the lower limbs and pelvis. The document also includes
recommendations on the management of superficial and perforating vein incompetence in patients with associated, more
advanced chronic venous diseases (CVDs), including edema, skin changes, or venous ulcers. Recommendations of the
Venous Guideline Committee are based on the Grading of Recommendations Assessment, Development, and Evaluation
(GRADE) system as strong (GRADE 1) if the benefits clearly outweigh the risks, burden, and costs. The suggestions are
weak (GRADE 2) if the benefits are closely balanced with risks and burden. The level of available evidence to support the
evaluation or treatment can be of high (A), medium (B), or low or very low (C) quality. The key recommendations of
these guidelines are: We recommend that in patients with varicose veins or more severe CVD, a complete history and
detailed physical examination are complemented by duplex ultrasound scanning of the deep and superficial veins
(GRADE 1A). We recommend that the CEAP classification is used for patients with CVD (GRADE 1A) and that the
revised Venous Clinical Severity Score is used to assess treatment outcome (GRADE 1B). We suggest compression
therapy for patients with symptomatic varicose veins (GRADE 2C) but recommend against compression therapy as the
primary treatment if the patient is a candidate for saphenous vein ablation (GRADE 1B). We recommend compression
therapy as the primary treatment to aid healing of venous ulceration (GRADE 1B). To decrease the recurrence of venous
ulcers, we recommend ablation of the incompetent superficial veins in addition to compression therapy (GRADE 1A). For
treatment of the incompetent great saphenous vein (GSV), we recommend endovenous thermal ablation (radiofrequency
or laser) rather than high ligation and inversion stripping of the saphenous vein to the level of the knee (GRADE 1B). We
recommend phlebectomy or sclerotherapy to treat varicose tributaries (GRADE 1B) and suggest foam sclerotherapy as an
option for the treatment of the incompetent saphenous vein (GRADE 2C). We recommend against selective treatment of
perforating vein incompetence in patients with simple varicose veins (CEAP class C2; GRADE 1B), but we suggest
treatment of pathologic perforating veins (outward flow duration>500ms, vein diameter>3.5 mm) located underneath
healed or active ulcers (CEAP class C5-C6; GRADE 2B). We suggest treatment of pelvic congestion syndrome and pelvic
varices with coil embolization, plugs, or transcatheter sclerotherapy, used alone or together (GRADE 2B). (J Vasc Surg
2011;53:2S-48S.)
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Guideline
No. Guideline title
GRADE of
recommendation
Level of
evidence
1. Strong A. High quality
2. Weak B Moderate
quality
C. Low or very
low quality
1. Clinical examination
1.1 For clinical examination of the lower limbs for chronic venous
disease, we recommend inspection (telangiectasia, varicosity,
edema, skin discoloration, corona phlebectatica,
lipodermatosclerosis, ulcer), palpation (cord, varicosity, tenderness,
induration, reflux, pulses, thrill, groin or abdominal masses),
auscultation (bruit), and examination of ankle mobility. Patients
should be asked for symptoms of chronic venous disease, which
may include tingling, aching, burning, pain, muscle cramps,
swelling, sensations of throbbing or heaviness, itching skin, restless
legs, leg tiredness, and fatigue.
1 A
2. Duplex scanning
2.1 We recommend that in patients with chronic venous disease, a
complete history and detailed physical examination are
complemented by duplex scanning of the deep and superficial
veins. The test is safe, noninvasive, cost-effective, and reliable.
1 A
2.2 We recommend that the four components of a complete duplex
scanning examination for chronic venous disease should be
visualization, compressibility, venous flow, including measurement
of duration of reflux, and augmentation.
1 A
2.3 We recommend that reflux to confirm valvular incompetence in the
upright position of the patients be elicited in one of two ways:
either with increased intra-abdominal pressure using a Valsalva
maneuver to assess the common femoral vein and the
saphenofemoral junction, or for the more distal veins, use of
manual or cuff compression and release of the limb distal to the
point of examination.
1 A
2.4 We recommend a cutoff value of 1 second for abnormally reversed
flow (reflux) in the femoral and popliteal veins and of 500 ms for
the great saphenous vein, the small saphenous vein, the tibial, deep
femoral, and the perforating veins.
1 B
2.5 We recommend that in patients with chronic venous insufficiency,
duplex scanning of the perforating veins is performed selectively.
We recommend that the definition of “pathologic” perforating
veins includes those with an outward flow of duration of 500 ms,
with a diameter of 3.5 mm and a location beneath healed or
open venous ulcers (CEAP class C5-C6).
1 B
3. Plethysmography
3.1 We suggest that venous plethysmography be used selectively for the
noninvasive evaluation of the venous system in patients with simple
varicose veins (CEAP class C2).
2 C
3.2 We recommend that venous plethysmography be used for the
noninvasive evaluation of the venous system in patients with
advanced chronic venous disease if duplex scanning does not
provide definitive information on pathophysiology (CEAP class
C3-C6).
1 B
4. Imaging studies
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4.1 We recommend that in patients with varicose veins and more
advanced chronic venous disease, computed tomography
venography, magnetic resonance venography, ascending and
descending contrast venography, and intravascular ultrasonography
are used selectively, including but not limited to post-thrombotic
syndrome, thrombotic or nonthrombotic iliac vein obstruction
(May-Thurner syndrome), pelvic congestion syndrome, nutcracker
syndrome, vascular malformations, venous trauma, tumors, and
planned open or endovascular venous interventions.
1 B
5. Laboratory evaluation
5.1 We recommend that in patients with varicose veins, evaluation for
thrombophilia is needed selectively for those with recurrent deep
venous thrombosis, thrombosis at a young age, or thrombosis in
an unusual site. Laboratory examinations are needed in patients
with long-standing venous stasis ulcers and in selected patients
who undergo general anesthesia for the treatment of chronic
venous disease.
1 B
6. Classification
6.1 We recommend that the CEAP classification be used for patients with
chronic venous disease. The basic CEAP classification is used for
clinical practice, and the full CEAP classification system is used for
clinical research.
1 A
6.2 We recommend that primary venous disorders, including simple
varicose veins, be differentiated from secondary venous
insufficiency and from congenital venous disorders because the
three conditions differ in pathophysiology and management.
1 B
7. Outcome assessment
7.1 We recommend that the revised Venous Clinical Severity Score is
used for assessment of clinical outcome after therapy for varicose
veins and more advanced chronic venous disease.
1 B
7.2 We recommend that a quality-of-life assessment is performed with a
disease-specific instrument to evaluate patient-reported outcome
and the severity of chronic venous disease.
1 B
7.3 We recommend duplex scanning for follow-up of patients after
venous procedures who have symptoms or recurrence of varicose
veins.
1 B
7.4 We recommend reporting procedure-related minor and major
complications after therapy.
1 B
8. Medical therapy
8.1 We suggest venoactive drugs (diosmin, hesperidin, rutosides,
sulodexide, micronized purified flavonoid fraction, or horse
chestnut seed extract [aescin]) in addition to compression for
patients with pain and swelling due to chronic venous disease, in
countries where these drugs are available.
2 B
8.2 We suggest using pentoxifylline or micronized purified flavonoid
fraction, if available, in combination with compression, to
accelerate healing of venous ulcers.
2 B
9. Compression therapy
9.1 We suggest compression therapy using moderate pressure (20 to 30
mm Hg) for patients with symptomatic varicose veins.
2 C
9.2 We recommend against compression therapy as the primary
treatment of symptomatic varicose veins in patients who are
candidates for saphenous vein ablation.
1 B
9.3 We recommend compression as the primary therapeutic modality for
healing venous ulcers.
1 B
9.4 We recommend compression as an adjuvant treatment to superficial
vein ablation for the prevention of ulcer recurrence.
1 A
10. Open venous surgery
10.1 For treatment of the incompetent great saphenous vein, we suggest
high ligation and inversion stripping of the saphenous vein to the
level of the knee.
2 B
10.2 To reduce hematoma formation, pain, and swelling, we recommend
postoperative compression. The recommended period of
compression in C2 patients is 1 week.
1 B
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10.3 For treatment of small saphenous vein incompetence, we recommend
high ligation of the vein at the knee crease, about 3 to 5 cm distal
to the saphenopopliteal junction, with selective invagination
stripping of the incompetent portion of the vein.
1 B
10.4 To decrease recurrence of venous ulcers, we recommend ablation of
the incompetent superficial veins in addition to compression
therapy.
1 A
10.5 We suggest preservation of the saphenous vein using the ambulatory
conservative hemodynamic treatment of varicose veins (CHIVA)
technique only selectively in patients with varicose veins, when
performed by trained venous interventionists.
2 B
10.6 We suggest preservation of the saphenous vein using the ambulatory
selective varicose vein ablation under local anesthesia (ASVAL)
procedure only selectively in patients with varicose veins.
2 C
10.7 We recommend ambulatory phlebectomy for treatment of varicose
veins, performed with saphenous vein ablation, either during the
same procedure or at a later stage. If general anesthesia is required
for phlebectomy, we suggest concomitant saphenous ablation.
1 B
10.8 We suggest transilluminated powered phlebectomy using lower
oscillation speeds and extended tumescence as an alternative to
traditional phlebectomy for extensive varicose veins.
2 C
10.9 For treatment of recurrent varicose veins, we suggest ligation of the
saphenous stump, ambulatory phlebectomy, sclerotherapy, or
endovenous thermal ablation, depending on the etiology, source,
location, and extent of varicosity.
2 C
11. Endovenous thermal ablation
11.1 Endovenous thermal ablations (laser and radiofrequency ablations)
are safe and effective, and we recommend them for treatment of
saphenous incompetence.
1 B
11.2 Because of reduced convalescence and less pain and morbidity, we
recommend endovenous thermal ablation of the incompetent
saphenous vein over open surgery.
1 B
12. Sclerotherapy of varicose veins
12.1 We recommend liquid or foam sclerotherapy for telangiectasia,
reticular veins, and varicose veins.
1 B
12.2 For treatment of the incompetent saphenous vein, we recommend
endovenous thermal ablation over chemical ablation with foam.
1 B
13. Treatment of perforating veins
13.1 We recommend against selective treatment of incompetent
perforating veins in patients with simple varicose veins (CEAP class
C2).
1 B
13.2 We suggest treatment of “pathologic” perforating veins that includes
those with an outward flow duration of 500 ms, with a diameter
of 3.5 mm, located beneath a healed or open venous ulcer
(CEAP class C5-C6).
2 B
13.3 For treatment of “pathologic” perforating veins, we suggest
subfascial endoscopic perforating vein surgery, ultrasonographically
guided sclerotherapy, or thermal ablations.
2 C
14. Treatment of pelvic varicose veins
14.1 We recommend noninvasive imaging with transabdominal and/or
transvaginal ultrasonography, computed tomography, or magnetic
resonance venography in selected patients with symptoms of pelvic
congestion syndrome or symptomatic varices in the distribution of
the pubis, labia, perineum, or buttocks.
1 C
14.2 We recommend retrograde ovarian and internal iliac venography in
patients with pelvic venous disease, confirmed or suspected by
noninvasive imaging studies, in whom an intervention is planned.
1 C
14.3 We suggest treatment of pelvic congestion syndrome and pelvic
varices with coil embolization, plugs, or transcatheter
sclerotherapy, used alone or together.
2 B
14.4 If less invasive treatment is not available or has failed, we suggest
surgical ligation and excision of ovarian veins to treat reflux.
2 B
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In the United States, an estimated 23% of adults have
varicose veins, and 6% have more advanced chronic venous
disease (CVD), including skin changes and healed or active
venous ulcers.1 Varicose veins have long been considered a
cosmetic problem that only affected emotional well-being
but were not the source of disability. Varicosities, however,
are frequently the cause of discomfort, pain, loss of working
days, disability, and deterioration of health-related quality
of life (QOL).1-3 Severe CVD may also lead to loss of limb
or loss of life.4
Evaluation of varicose veins has greatly progressed in
the past 2 decades with the widespread availability of duplex
ultrasonography.5 The treatment of varicose veins has also
undergone dramatic changes with the introduction of per-
cutaneous endovenous ablation techniques, including en-
dovenous laser therapy (EVLA),6,7 radiofrequency ablation
(RFA),8 and liquid or foam sclerotherapy.9,10 Open surgi-
cal treatment with stripping of the varicose veins performed
under general anesthesia, with the associated pain, poten-
tial for wound complications, and loss of working days, has
been largely replaced by percutaneous office-based proce-
dures that can be performed under local or tumescent
anesthesia with similar early and midterm results but with
less discomfort to the patient, improved early QOL, and
earlier return to work.11-13
The purpose of this document is to report recently
formulated current recommendations for the evaluation
and treatment of patients with varicose veins of the lower
limbs and pelvis. These Guidelines also include recommen-
dations for management of superficial and perforating vein
incompetence in patients with associated, more advanced
CVDs, such as venous edema, skin changes, or ulcerations.
To accomplish this task, a joint Venous Guideline Commit-
tee of the Society for Vascular Surgery (SVS) and the
American Venous Forum (AVF) was established.
Under no circumstance should these Guidelines be
construed in practice or legal terms as defining the “stan-
dard of care,” which is solely determined by the condition
of the individual patient, treatment setting, and other fac-
tors. Individual factors in a given patient, such as symptom
variance or combinations, comorbidities, work, and socio-
economic factors may dictate a different approach than that
described in the Guidelines. Because technology and dis-
ease knowledge is rapidly expanding, new approaches may
supersede these recommendations. As important new in-
formation on management of varicose veins and related
CVD becomes available, these recommendations will be
revised without delay.
METHODOLOGY OF GUIDELINES
Evidence-based medicine is the conscientious, explicit,
and judicious use of the current best evidence in making
decisions about the care of individual patients.14 Guidelines
for the care of patients with varicose veins, as recommended
in this report, are based on scientific evidence. The need for
adopting evidence-based guidelines and reporting stan- vards for venous diseases has long been recognized by
nternational experts15 and by leaders of the SVS16 and
VF.17-20 To define current guidelines, members of the
enous Guideline Committee reviewed the relevant litera-
ure, including previously published consensus documents
nd guidelines,21-31 meta-analyses,6-12,32-42 the AVF re-
orts on the Venous Summit at the 2006 and 2009 Pacific
ascular Symposiums13,43-46 and considered the recom-
endations published in the third edition of the Handbook
f Venous Disorders, Guidelines of the American Venous
orum.47
The guidelines in this publication are based on the
rading of Recommendations Assessment, Development,
nd Evaluation (GRADE) system, as it was described by
uyatt et al (Table I).48 For each guideline, the letter A, B,
r C marks the level of current evidence. The grade of
ecommendation of a guideline can be strong (1) or weak
2), depending on the risk and burden of a particular
iagnostic test or a therapeutic procedure to the patient vs
he expected benefit. The words “we recommend” are used
or GRADE 1—strong recommendations—if the benefits
learly outweigh risks and burdens, or vice versa; the words
we suggest” are used for GRADE 2—weak recommenda-
ions—when the benefits are closely balanced with risks and
urdens.
EFINITIONS
In this document, the updated terminology for super-
cial, perforating, and deep veins of the leg and pelvis are
sed.49,50 Definitions of varicose and spider veins as well
s other manifestations of CVD follow recommendations
f the CEAP classification and the recent update on
enous terminology of the International Committee of
he AVF.51,52
Varicose veins of the lower limbs are dilated subcuta-
eous veins that are 3 mm in diameter measured in the
pright position.53 Synonyms include varix, varices, and
aricosities. Varicosity can involve the main axial superficial
eins—the great saphenous vein (GSV) or the small saphe-
ous vein (SSV)—or any other superficial vein tributaries of
he lower limbs.
Most varicose veins are due to primary venous disease.
he most frequent cause is likely an intrinsic morphologic
r biochemical abnormality in the vein wall, although the
tiology can also be multifactorial. Labropoulos et al54
roposed that the origin of venous reflux in patients with
rimary varicose veins can be local or multifocal structural
eakness of the vein wall and that this can occur together or
ndependently of proximal saphenous vein valvular incom-
etence. Varicosities can also develop as a result of second-
ry causes, such as previous deep vein thrombosis (DVT),
eep venous obstruction, superficial thrombophlebitis, or
rteriovenous fistula. Varicose veins may also be congenital
nd present as a venous malformation.
Varicosities are manifestations of CVD.51,52 CVD in-
ludes various medical conditions of long duration, all
nvolving morphologic and functional abnormalities of the
enous system manifested by symptoms or signs (or both),
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chronic venous disorder is reserved for the full spectrum of
venous abnormalities and includes dilated intradermal veins
and venules between 1 and 3 mm in diameter (spider veins,
reticular veins, telangiectasia; CEAP class C1).
Varicose veins can progress to a more advanced form of
chronic venous dysfunction such as chronic venous insuffi-
ciency (CVI).55,56 In CVI, increased ambulatory venous
hypertension initiates a series of changes in the subcuta-
neous tissue and the skin: activation of the endothelial
cells, extravasation of macromolecules and red blood
cells, diapedesis of leukocytes, tissue edema, and chronic
inflammatory changes most frequently noted at and
above the ankles.41,53 Limb swelling, pigmentation, li-
podermatosclerosis, eczema, or venous ulcerations can
develop in these patients.
THE SCOPE OF THE PROBLEM
In the adult Western population, the prevalence of
varicose veins is20% (range, 21.8%-29.4%), and about 5%
(range, 3.6%-8.6%) have venous edema, skin changes or
venous ulcerations. Active venous ulcers are present in up
to 0.5%, and between 0.6% and 1.4% have healed ulcers.57
On the basis of estimates of the San Diego epidemiologic
study, more than 11 million men and 22 million women
between the ages of 40 and 80 years in the United States
Table I. Grading recommendations according to evidence
Grade
Description of
recommendation Benefit vs risk and burdens
1A Strong recommendation,
high-quality evidence
Benefits clearly outweigh
risk and burdens, or vice
versa
1B Strong recommendation,
moderate quality
evidence
Benefits clearly outweigh
risk and burdens, or vice
versa
1C Strong recommendation,
low-quality or very
low-quality evidence
Benefits clearly outweigh
risk and burdens, or vice
versa
2A Weak recommendation,
high-quality evidence
Benefits closely balanced
with risks and burden
2B Weak recommendation,
moderate-quality
evidence
Benefits closely balanced
with risks and burden
2C Weak recommendation,
low-quality or very
low-quality evidence
Uncertainty in the estimates
of benefits, risks, and
burden; benefits, risk, and
burden may be closely
balanced
RCT, Randomized controlled trial.
aAdapted from Guyatt et al.48 Used with permission.have varicose veins, and 2 million adults have advanced pVD, with skin changes or ulcers.1 The incidence of post-
hrombotic venous ulcers has not changed in the past 2
ecades for women, and it recently increased in men.58 In
he United States each year, at least 20,556 patients receive
new diagnosis of venous ulcers.3
The Bonn Vein Study,59 which enrolled 3072 ran-
omly selected participants (1722 women and 1350 men),
ged from 18 to 79 years, found symptoms of CVD in
9.1% of men and in 62.1% of women. Also reported were
aricose veins without edema or skin changes in 14.3%
12.4% men, 15.8% women), edema in 13.4% (11.6% men,
4.9% women), skin changes in 2.9% (3.1% men, 2.7%
omen), and healed or active ulceration in 0.6% or 0.1%,
espectively. A French cross-sectional survey found varicose
eins in 23.7% of men and 46.3% of women.60
The National Venous Screening Program, under the
uspices of the AVF, screened 2234 Americans for venous
isease.61 The participants’ mean age was 60 years, 77%
ere women, and 80% were white. The CEAP clinical
lassification of C0 to C6 was 29%, 29%, 23%, 10%, 9%,
.5%, and 0.5%, respectively. Reflux or obstruction was
oted in 37% and 5% of participants, respectively.
Progression of primary varicosity to severe CVI and
enous ulcer is not rare: in the North American subfascial
ndoscopic perforator surgery (SEPS) registry, more pa-
ients with advanced CVI had primary venous disease than
Methodologic quality of
supporting evidence Implications
without important
itations or overwhelming
ence from observational
dies
Strong recommendation, can apply
to most patients in most
circumstances without
reservation
with important limitations
onsistent results,
thodologic flaws, indirect,
mprecise) or exceptionally
ng evidence from
ervational studies
Strong recommendation, can apply
to most patients in most
circumstances without
reservation
vational studies or case
es
Strong recommendation but may
change when higher quality
evidence becomes available
without important
itations or overwhelming
ence from observational
dies
Weak recommendation, best action
may differ depending on
circumstances or patients’ or
societal values
with important limitations
onsistent results,
thodologic flaws, indirect,
mprecise) or exceptionally
ng evidence from
ervational studies
Weak recommendation, best action
may differ depending on
circumstances or patients’ or
societal values
vational studies or case
es
Very weak recommendations; other
alternatives may be equally
reasonablea
RCTs
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advanced CVD, studied with phlebography, never had a
previous DVT.
Varicose veins and venous ulcers can be a great
financial burden to patients and to society. Varicose veins
and associated complications may lead to chronic pain,
disability, decreased quality of life (QOL), loss of work-
ing days, and early retirement. In the United States, the
direct medical cost of CVD has been estimated to be
between $150 million and $1 billion annually.3,4 In the
United Kingdom, 2% of the national health care budget
per year (US $1 billion) is spent on the management of
leg ulcers.1
Venous ulcer is an under-recognized and undertreated
disease. A recently published supplement of the Journal of
Vascular Surgery details the noble goal of the Pacific Vas-
cular Symposium 6 (PVS6) to lead a call to action to
formulate a doable and achievable plan to reduce the inci-
dence of venous ulcers in the United States by 50% in 10
years.64
ANATOMY
During the past decade, new venous terminology has
been developed and adopted by vascular societies around
the world.47,49,61 The success of assigning uniform names
to common veins was accompanied by new information on
anatomy obtained with duplex ultrasonography, three-
dimensional computed tomography (CT), and magnetic
resonance (MR) imaging; all these resulted in better under-
standing of the anatomy of veins and the pathology of
CVD.33,62
Superficial veins
Superficial veins of the lower limbs are those located
between the deep fascia, covering the muscles of the
limb, and the skin. The main superficial veins are the
GSV and the SSV. All previous names used to describe
these vessels (greater, long, lesser) should be abandoned.
The GSV originates from the medial superficial veins of
the dorsum of the foot and ascends in front of the medial
malleolus along the medial border of the tibia, next to
the saphenous nerve (Fig 1). There are posterior and
anterior accessory saphenous veins in the calf and the
thigh. The saphenofemoral junction (SFJ) is the conflu-
ence of superficial inguinal veins, comprising the GSV
and the superficial circumflex iliac, superficial epigastric,
and external pudendal veins. The GSV in the thigh lies in
the saphenous subcompartment of the superficial com-
partment, between the saphenous fascia and the deep
fascia.
The SSV is the most important posterior superficial vein
of the leg (Fig 2). It originates from the lateral side of the
foot and drains blood into the popliteal vein, joining it
usually just proximal to the knee crease. The intersaphe-
nous vein (vein of Giacomini), which runs in the posterior
thigh, connects the SSV with the GSV.65 veep veins
Deep veins accompany the main arteries of the limb and
elvis. The deep veins of the calf (anterior, posterior tibial,
nd peroneal veins) are paired structures, and the popliteal
nd femoral veins may also be paired. The gastrocnemius
nd soleal veins are important deep tributaries. The old
erm superficial femoral vein has been replaced by the new
erm femoral vein.52 The femoral vein connects the popli-
eal to the common femoral vein.
The pelvic veins include the external, internal, and
ommon iliac veins, which drain into the inferior vena cava
IVC). Large gonadal veins drain into the IVC on the right
nd the left renal vein on the left.
erforating veins
Perforating veins connect the superficial to the deep
enous system (Fig 1). They pass through the deep fascia
hat separates the superficial compartment from the deep.
ommunicating veins connect veins within the same sys-
em. The most important leg perforating veins are the
edial calf perforators.66 The posterior tibial perforating
ig 1. Medial superficial and perforating veins of the lower limb.
Used with permission of Mayo Foundation for Medical Educa-
ion and Research.)eins (Cockett perforators in the old nomenclature) con-
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Volume 53, Number 16S Gloviczki et al 9Snect the posterior accessory GSV of the calf (the posterior
arch vein in the old nomenclature) with the posterior tibial
veins and form the lower, middle, and upper groups. They
are located just behind the medial malleolus (lower), at 7 to
9 cm (middle) and at 10 to 12 cm (upper) from the lower
edge of the malleolus. The distance between these perfora-
tors and the medial edge of the tibia is 2 to 4 cm.66 (Fig 1).
Paratibial perforators connect the main GSV trunk with
the posterior tibial veins. In the distal thigh, perforators
of the femoral canal usually connect directly the GSV to
the femoral vein.
Venous valves
Bicuspid venous valves are important structures assist-
ing unidirectional flow in the normal venous system. The
GSV usually has at least 6 valves (range, 4-25), with a
constant valve present within 2 to 3 cm of the SFJ in 85% of
cases,67 and the SSV has a median of 7 to 10 valves (range,
4-13).68 There are valves in the deep veins of the lower
limb, but the common femoral or external iliac vein has
only one valve in about 63% of cases.68 In 37%, there is no
valve in the common femoral or external iliac veins. The
internal iliac vein has a valve in 10%; its tributaries have
Fig 2. Posterior superficial and perforating veins of the leg. (Used
with permission of Mayo Foundation for Medical Education and
Research.)valves in 9%.69 fIAGNOSTIC EVALUATION
linical examination
Patients with varicose veins may present with no symp-
oms at all; the varices are then of cosmetic concern only,
ith an underlying psychologic impact. Psychologic con-
erns related to the cosmetic appearance of varicose veins
ill, however, reduce a patient’s QOL in many cases.
Symptoms related to varicose veins or more advanced
VD include tingling, aching, burning, pain, muscle
ramps, swelling, sensations of throbbing or heaviness,
tching skin, restless legs, leg tiredness, and fatigue.70 Al-
hough not pathognomonic, these symptoms suggest
VD, particularly if they are exacerbated by heat or depen-
ency noted during the course of the day and relieved by
esting or elevating the legs or by wearing elastic stockings
r bandages.51 Pain during and after exercise that is relieved
ith rest and leg elevation (venous claudication) can also be
aused by venous outflow obstruction caused by previous
VT or by narrowing or obstruction of the common iliac
eins (May-Thurner syndrome).69-71 Diffuse pain is more
requently associated with axial venous reflux, whereas poor
enous circulation in bulging varicose veins usually causes
ocal pain.
History. A thorough medical history is essential in the
atient’s evaluation and may establish the diagnosis of
rimary, secondary, or congenital varicosities. Questions
o patients who present with varicose veins should address
revious DVT or thrombophlebitis, established thrombo-
hilia, medication history (particularly birth control pills),
moking, pregnancies, and a family history of varicosity or
hrombotic disorders. Premenopausal women with varicose
eins should also be questioned for symptoms of pelvic
ongestion syndrome (pelvic pain, aching, or heaviness;
yspareunia). Advanced age is the most important risk
actor for varicose veins and for CVI. A positive family
istory, female sex, and multiparity are also risk factors for
aricose veins, and a positive family history and obesity are
isk factors for CVI.57
Physical examination. Clinical evaluation should fo-
us on signs of venous disease, and examination in the
tanding patient in a warm room, with good light, should
stablish the size, location, and distribution of varicose
eins. Inspection and palpation are essential parts of the
xamination, and auscultation (bruit) is particularly helpful
n those with vascular malformation and arteriovenous
stula.71 Varicose dilations or venous aneurysms, palpable
ord in the vein, tenderness, a thrill, bruit, or pulsatility
hould be recorded. In addition, the presence of spider
eins or telangiectasia, limb swelling that is usually partially
itting or nonpitting, induration, pigmentation, lipoder-
atosclerosis, atrophie blanche, eczema, dermatitis, skin
iscoloration, increased skin temperature, and healed or
ctive ulcers should be documented.
Ankle mobility should also be examined, because pa-
ients with advanced venous disease frequently have de-
reased mobility in the ankle joints. Sensory and motor
unctions of the limb and foot are assessed to help differen-
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logic problem. An abdominal mass or lymphadenopathy
may be a clue to venous compression and outflow
obstruction.
Corona phlebectatica (ankle flare or malleolar flare)
is a fan-shaped pattern of small intradermal veins located
around the ankle or the dorsum of the foot. This is
considered an early sign of advanced venous disease. The
pattern of the varicose veins should be established, be-
cause perineal, vulvar, or groin varicosity can be a sign of
iliac vein obstruction or internal iliac vein or gonadal
vein incompetence causing pelvic congestion syndrome.
Scrotal varicosity may be a sign of gonadal vein incom-
petence, left renal vein compression between the supe-
rior mesenteric artery and the aorta (nutcracker syn-
drome), or occasionally, even IVC lesions or renal
carcinoma. Varicose veins of the upper thigh can be
caused by inferior gluteal vein reflux.72,73
Classic tourniquet tests for saphenous or perforator
incompetence or deep venous occlusion (Trendelenburg
test, Ochsner-Mahorner test, Perthes test)71 are rarely used
today; they are mostly of historic interest and should be
used in rare instances, when duplex scanning or Doppler
studies are not available. Distal palpation and proximal
percussion of the saphenous vein, however, are useful tests
to suggest valvular incompetence.
Skin lesions, such as capillary malformations, tumors,
onychomycosis, or excoriations, should be noted and a
complete pulse examination performed to exclude un-
derlying peripheral arterial disease. An aneurysmal sa-
phenous vein can be misdiagnosed as a femoral hernia or
vice versa. The presence of a longer limb, lateral varicos-
ity noted soon after birth, and associated capillary mal-
formations are tip-offs for congenital venous malforma-
tion (Klippel-Trénaunay syndrome),74,75 whereas edema
of the dorsum of the foot, squaring of the toes, thick
skin, and nonpitting edema are signs of chronic
lymphedema. The physical examination can be comple-
mented by a handheld Doppler examination, although
the latter does not replace evaluation of the venous
circulation with color duplex scanning.
The Guideline Committee recommends using the
basic CEAP classification76,77 (see Classification of
chronic venous disorders later in the Guidelines) to docu-
ment the clinical class, etiology, anatomy, and patho-
physiology (CEAP) of CVD (Tables II and III). We also
recommend use of the revised Venous Clinical Severity
Score (VCSS)78 to grade the severity of CVD (see Out-
come assessment; Table IV).
The aim of the clinical evaluation is not only to deter-
mine the presenting signs and symptoms and the type of
venous disease (primary, secondary, congenital) but also to
exclude other etiologies, including peripheral arterial dis-
ease, rheumatoid disease, infection, tumor, or allergies. The
physician should also establish the degree of disability
caused by the venous disease and its impact on the patient’s
QOL. suplex scanning
Duplex scanning is recommended as the first diagnostic
est for all patients with suspected CVD.5,79 The test is safe,
oninvasive, cost-effective, and reliable. It has much better
iagnostic accuracy in the assessment of venous insuffi-
iency than continuous-wave Doppler ultrasonography.80
-mode imaging permits accurate placement of the pulsed
oppler sample volume, and the addition of color makes it
asier to establish obstruction, turbulence, and the direc-
ion of venous and arterial flow.44 Duplex scanning is
xcellent for the evaluation of infrainguinal venous obstruc-
ion and valvular incompetence.81 It also differentiates
etween acute venous thrombosis and chronic venous
hanges.82,83
Technique of the examination. The technique of
enous duplex scanning has been described in detail previ-
usly by several authors.80,83-88 The pulsed-wave Doppler
f 4 to 7-MHz linear array tranducers are used most
requently for the deeper veins, with the higher-frequency
robes used more to assess the superficial veins. Evaluation
f reflux in the deep and superficial veins with duplex
able II. The CEAP classification
EAP Description
. Clinical
classification
C0 No visible or palpable signs of venous
disease
C1 Telangiectases or reticular veins
C2 Varicose veins
C3 Edema
C4a Pigmentation and/or eczema
C4b Lipodermatosclerosis and/or atrophie
blanche
C5 Healed venous ulcer
C6 Active venous ulcer
CS Symptoms, including ache, pain, tightness,
skin irritation, heaviness, muscle cramps,
as well as other complaints attributable
to venous dysfunction
CA Asymptomatic
. Etiologic
classification
Ec Congenital
Ep Primary
Es Secondary (postthrombotic)
En No venous etiology identified
. Anatomic
classification
As Superficial veins
Ap Perforator veins
Ad Deep veins
An No venous location identified
. Pathophysiologic
classification
Pr Reflux
Po Obstruction
Pr,o Reflux and obstruction
Pn No venous pathophysiology identifiable
dapted from Eklöf et al.77 Used with permission.canning should be performed with the patient upright,
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weight taken on the opposite limb.5 The supine position
gives both false-positive and false-negative results of
reflux.84
The examination is started below the inguinal liga-
ment, and the veins are examined in 3- to 5-cm intervals.
For a complete examination, all deep veins of the leg are
examined, including the common femoral, femoral, deep
femoral, popliteal, peroneal, soleal, gastrocnemial, anterior,
and posterior tibial veins. The superficial veins are then
evaluated, including the GSV, the SSV, the accessory sa-
phenous veins, and the perforating veins.
The four components that should be included in a
complete duplex scanning examination for CVD are (1)
visibility, (2) compressibility, (3) venous flow, including
measurement of the duration of reflux, and (4) augmenta-
tion. Asymmetry in flow velocity, lack of respiratory varia-
tions in venous flow, and waveform patterns at rest and
during flow augmentation in the common femoral veins
indicate proximal obstruction. Reflux can be elicited in two
ways: increased intra-abdominal pressure using a Valsalva
maneuver for the common femoral vein or the SFJ, or by
manual compression and release of the limb distal to the
point of examination. The first is more appropriate for
evaluation of reflux in the common femoral vein and at the
SFJ, whereas compression and release is the preferred tech-
nique more distally on the limb.84 The advantage of a distal
cuff deflation was emphasized by van Bemmelen et al.85
The cutoff value for abnormally reversed venous flow
(reflux) in the saphenous, tibial, and deep femoral veins has
been 500 ms.81 International consensus documents previ-
ously recommended 0.5 seconds as a cutoff value for all
veins to use for lower limb venous incompetence.5,22,86
This value is, however, longer, 1 second, for the femoral
Table III. Venous anatomic segment classification
Superficial veins
1. Telangiectases/reticular veins
2. GSV above knee
3. GSV below knee
4. Short saphenous vein
5. Nonsaphenous veins
Deep veins
6. Inferior vena cava
7. Common iliac vein
8. Internal iliac vein
9. External iliac vein
10. Pelvic: gonadal, broad ligament veins, other
11. Common femoral vein
12. Deep femoral vein
13. Femoral vein
14. Popliteal vein
15. Crural veins: anterior tibial, posterior tibial,
peroneal veins (all paired)
16. Muscular veins: gastrocnemius, soleal, other
Perforating veins
17. Thigh perforator veins
18. Calf perforator veins
Adapted from Eklöf et al.77 Used with permission.and popliteal veins.81 For the perforating veins, cutoff malues of both 350 ms and 500 ms have been suggested.5,81
he Committee recommends 500 ms as the cutoff value for
aphenous, tibial, deep femoral, and perforating vein in-
ompetence, and 1 second for femoral and popliteal vein
ncompetence.
Perforating veins have been evaluated in patients with
dvanced disease, usually in those with healed or active
enous ulcers (CEAP class C5-C6) or in those with recur-
ent varicose veins after previous interventions. The diam-
ter of clinically relevant “pathologic” perforators (eg, be-
eath healed or open venous ulcer) may predict valve
ncompetence. In a study by Labrapoulos et al,87 a perfo-
ator vein diameter 3.9 mm had a high specificity (96%)
ut a low sensitivity (73%) to predict incompetence, given
hat almost one-third of the incompetent perforators had a
iameter of 3.9 mm.87,88 Sandri et al,89 however, found
hat a perforator diameter of3.5 mm was associated with
eflux in 90% of cases. The SVS/AVF Guideline Com-
ittee definition of “pathologic” perforating veins includes
hose with outward flow of 500 ms, with a diameter of
3.5 mm, located beneath a healed or open venous ulcer
CEAP class C5-C6).
5,81,88,89
Duplex findings in CVD. A duplex evaluation of
atients with CVD demonstrated that superficial vein reflux
as present in 90% and that 70% to 80% have reflux in the
SV.90 Patients with venous ulcers usually have multilevel
isease affecting the superficial, deep, and perforating veins.
uplex evaluations have also revealed that 74% to 93% of all
atients with venous ulcers have superficial vein incompe-
ence, with superficial venous reflux being the only abnor-
ality in 17% to 54% of the limbs. Of 239 patients with
enous ulcers evaluated with duplex scanning in three
ifferent studies, 144 (60.3%) had incompetent perforating
eins, and 141 (59%) had deep vein incompetence or
bstruction.91-93
lethysmography
Plethysmography (air or strain-gauge) is used for the
oninvasive evaluation of calf muscle pump function, global
enous reflux, and venous outflow obstruction.86,94-96 Strain-
auge plethysmography is usually performed with a modified
rotocol of Struckmann, validated previously by comparison
ith simultaneously recorded ambulatory venous pressure
easurements.97-100 Strain-gauge or air plethysmography
onsists of exercise venous plethysmography, measurement of
assive refill and drainage, and outflow plethysmography.
lethysmography quantifies venous reflux and obstruction
nd has been used to monitor venous functional changes and
ssess physiologic outcome of surgical treatments.95 For more
etails of these examinations, the reader is referred to original
rticles94,96,97 and a recent relevant book chapter.100
The use of plethysmography is less frequently indicated
n patients with CEAP C2 disease (simple varicose veins),
ut these studies provide information on venous function
n patients with CVI, and they are complementary exami-
ation to duplex scanning. Examples for use in patients may
nclude those with suspected outflow obstruction but nor-
al duplex findings or those suspected of having venous
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or obstruction was noted on duplex scanning. Air plethys-
mography remains one of the few noninvasive techniques
that can quantify reflux reliably98,99 although other param-
eters have been reported to be variably useful. The Guide-
line Committee encourages using air plethysmography as
“best practice” in the evaluation of patients with advance
CVD if duplex scanning does not provide definitive diag-
nosis on pathophysiology (CEAP C3-C6).
Imaging studies
Contrast venography. Ascending or descending con-
trast venography for varicosities or other forms of CVD is
Table IV. Revised Venous Clinical Severity Score
None: 0 Mild: 1
Pain or other discomfort (ie,
aching, heaviness, fatigue,
soreness, burning); presumes
venous origin
None Occasional pain or
discomfort (ie, n
restricting regula
activity)
Varicose veins
“Varicose” veins must be 3
mm in diameter to qualify in
the standing position
None Few: scattered (ie,
branch varicositie
clusters); also inc
corona phlebecta
(ankle flare)
Venous edema
Presumes venous origin None Limited to foot and
area
Skin pigmentation
Presumes venous origin; does
not include focal
pigmentation over varicose
veins or pigmentation due to
other chronic diseases (ie,
vasculitis purpura)
None
or
focal
Limited to perimal
area
Inflammation
More than just recent
pigmentation (ie, erythema,
cellulitis, venous eczema,
dermatitis)
None Limited to perimal
area
Induration
Presumes venous origin of
secondary skin and
subcutaneous changes (ie,
chronic edema with fibrosis,
hypodermitis); includes white
atrophy and
lipodermatosclerosis
None Limited to perimal
area
No. of active ulcers 0 1
Active ulcer duration (longest
active)
NA 3 mo
Active ulcer size (largest active) NA Diameter 2 cm
Use of compression
therapy None: 0 Occasi
Not used Intermitt
stockin
Adapted from Vasquez et al.123 Used with permission.performed selectively in patients with deep venous obstruc- aion, in patients with post-thrombotic syndrome, and if
ndovenous or open surgical treatment is planned. It can be
sed with direct venous pressure measurements to evaluate
atients with varicose veins and associated iliac vein ob-
truction (May-Thurner syndrome). Contrast venography
s routinely used in CVD to perform endovenous proce-
ures, such as angioplasty or venous stenting or open
enous reconstructions.
CT and MR venography. Patients with simple vari-
ose veins rarely require imaging studies more sophisticated
han duplex ultrasonography. The techniques of CT and
R imaging have progressed tremendously in the past
ecade, and they provide excellent three-dimensional im-
Moderate: 2 Severe: 3
y
Daily pain or other discomfort
(ie, interfering with but not
preventing regular daily
activities)
Daily pain or discomfort
(ie, limits most
regular daily
activities)
ed Confined to calf or thigh Involves calf and thigh
e Extends above ankle but below
knee
Extends to knee and
above
Diffuse over lower third of calf Wider distribution
above lower third of
calf
Diffuse over lower third of calf Wider distribution
above lower third of
calf
Diffuse over lower third of calf Wider distribution
above lower third of
calf
2 3
3 mo but 1 y Not healed for 1 y
Diameter 2-6 cm Diameter 6 cm
1 Frequent: 2 Always: 3
se of Wears stockings
most days
Full compliance:
stockingsother
ot
r dail
isolat
s or
ludes
tica
ankl
leolar
leolar
leolar
onal:
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gsging of the venous system. MR and CT are both suitable
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Volume 53, Number 16S Gloviczki et al 13Sto identify pelvic venous obstruction or iliac vein stenosis in
patients with lower limb varicosity when a proximal ob-
struction or iliac vein compression (May-Thurner syn-
drome) is suspected.101 They are suitable to establish left
renal vein compression (nutcracker syndrome),102 gonadal
vein incompetence, and pelvic venous congestion syn-
drome. MR imaging with gadolinium is especially useful in
evaluating patients with vascular malformations, including
those with congenital varicose veins.
Intravascular ultrasonography. Intravascular ultra-
sonography (IVUS) has been used successfully to evaluate
iliac vein compression or obstruction and to monitor pa-
Guideline 1. Clinical examination
Guideline
No. 1. Clinical examinatio
1.1 For clinical examination of the lower limbs for chroni
inspection (telangiectasia, varicosity, edema, skin di
phlebectatica, lipodermatosclerosis, ulcer), palpatio
induration, reflux, pulses, thrill, groin or abdomina
and examination of ankle mobility. Patients should
chronic venous disease, which may include tingling
cramps, swelling, sensations of throbbing or heavin
tiredness, and fatigue.
Guideline 2. Duplex scanning
Guideline
No. 2. Duplex scanning
2.1 We recommend that in patients with chronic venous
detailed physical examination are complemented b
and superficial veins. The test is safe, noninvasive,
2.2 We recommend that the four components of a comp
examination for chronic venous disease should be
venous flow, including measurement of duration o
2.3 We recommend that reflux to confirm valvular incom
position of the patients be elicited in one of two w
abdominal pressure using a Valsalva maneuver to a
and the saphenofemoral junction, or for the more
cuff compression and release of the limb distal to t
2.4 We recommend a cutoff value of 1 second for abnorm
the femoral and popliteal veins and of 500 ms for
small saphenous vein, the tibial, deep femoral, and
2.5 We recommend that in patients with chronic venous
of the perforating veins is performed selectively. W
definition of “pathologic” perforating veins includ
of duration of 500 ms, with a diameter of 3.5
healed or open venous ulcers (CEAP class C5-C6).tients after venous stenting.101 For patients with varicose ueins, IVUS should be used selectively in those with sus-
ected or confirmed iliac vein obstruction. IVUS is impor-
ant in assessing the morphology of the vessel wall, identi-
ying lesions such as trabeculations, frozen valves, mural
hickness, and external compression that are not seen with
onventional contrast venography, and it provides mea-
urements in assessing the degree of stenosis. In addition,
VUS confirms the position of the stent in the venous
egment and the resolution of the stenosis.101
aboratory evaluation
Patients with varicose veins are usually operated on
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May Supplement 201114S Gloviczki et altests are not routinely performed. In those with recurrent
DVT, thrombosis at a young age, or thrombosis in an
unusual site, we recommend screening for thrombophilia.
Laboratory examination is also needed in patients with
long-standing recalcitrant venous ulcers. One study found
2.1% of venous and arterial ulcers had a secondary etiology,
including neoplasia, chronic inflammation, sickle cell dis-
ease, vasculitis, rheumatoid arthritis, pyoderma gangreno-
sum, and hydroxyurea.103 Patients who undergo general
anesthesia for treatment of CVD may need a blood cell
count or an electrolyte panel.
CLASSIFICATION OF CVD
The cornerstone for management of CVD is the proper
diagnosis and accurate classification of the underlying ve-
nous problem, which create the base for correctly directed
treatment. The clinical and laboratory evaluation of the
patient with varicose veins or more advanced CVD should
be completed by establishing the clinical class of the disease.
The CEAP classification was developed by the AVF in 1994
Guideline 3. Plethysmography
Guideline
No. 3. Plethysmography
3.1 We suggest that venous plethysmography be used
noninvasive evaluation of the venous system in
varicose veins (CEAP class C2).
3.2 We recommend that venous plethysmography be
evaluation of the venous system in patients with
venous disease if duplex scanning does not pro
information on pathophysiology (CEAP class C
Guideline 4. Imaging studies
Guideline
No. 4. Imaging studies
4.1 We recommend that in patients with varicose vein
chronic venous disease, computed tomography
resonance venography, ascending and descendi
and intravascular ultrasonography are used sele
including but not limited to post-thrombotic sy
nonthrombotic iliac vein obstruction (May-Thu
congestion syndrome, nutcracker syndrome, va
venous trauma, tumors, and planned open or e
interventions.and later revised in 2004.76,77 The classification is based on mlinical signs of venous disease (C), etiology (E), anatomy
A), and the underlying pathophysiology (P).
Clinical class includes the full spectrum of venous dis-
rders, from no signs of visible venous disease (C0) to
elangiectasia or reticular veins (C1), varicose veins (C2),
dema (C3), skin changes, such as pigmentation or eczema
C4a) or lipodermatosclerosis or atrophie blanche (C4b),
nd healed (C5) or active (C6) ulcer. The presence or
bsence of symptoms is also recorded as S (symptomatic) or
(asymptomatic).
Etiology can be congenital (Ec), primary (Ep), or sec-
ndary (Es).
The anatomic classification separates superficial venous
isease (As) from involvement of the perforators (Ap) or
eep veins (Ad). Failure to identify an anatomic location is
lso coded (An).
Pathophysiology of the disease can be reflux (Pr), ob-
truction (Po), or both. Failure to identify venous patho-
hysiology is also noted (Pn). Table II includes the full
EAP classification, and Table III lists the venous seg-
GRADE of
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Level of
evidence
1. Strong A. High
quality
2. Weak B. Moderate
quality
C. Low or very
low quality
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Volume 53, Number 16S Gloviczki et al 15SThe basic CEAP classification is a simplified version,
suitable and easy for office use, and does not have the
details of the comprehensive CEAP classification, which
functions more as a research tool. As discussed in more
detail by Meissner et al,13 for a patient with primary,
symptomatic varicose veins and full saphenous and per-
forator incompetence (anatomic segments 2, 3, and 18
in Table III) with a small healed venous ulcer and skin
pigmentation, the comprehensive CEAP classification
would be C2,4a,5,SEpAs,p,Pr2,3,18.
Using the basic CEAP, the same patient would be
classified as C5,SEpAs,pPr. In the basic CEAP classifica-
tion, only the highest score is used to denote the clinical
class and only the main anatomic groups (s, p, and d) are
noted.
The revised format of the classification77 includes two
elements in addition to the C-E-A-P findings: the date of
the examination and the level of the diagnostic evaluation:
Level 1: History, physical examination, Doppler examina-
tion (handheld)
Level 2: Noninvasive—duplex scan, plethysmography
Level 3: Invasive or complex evaluation—contrast venog-
raphy, venous pressure measurements, IVUS, CT
Guideline 5. Laboratory evaluation
Guideline
No. 5. Laboratory evaluation
5.1 We recommend that in patients with chronic ven
for thrombophilia is needed selectively for tho
vein thrombosis, thrombosis at a young age, o
unusual site. Laboratory examination is neede
standing venous stasis ulcers (blood cell count
and in selected patients who undergo general
treatment of chronic venous disease.
Guideline 6. Classification
Guideline
No. 6. Classification
6.1 We recommend that the CEAP classification be use
veins. The basic CEAP classification is used for c
CEAP classification system is used for clinical res
6.2 We recommend that primary venous disorders, inc
veins, be differentiated from secondary venous in
congenital venous disorders because the three co
pathophysiology and management.venography, MR venography lThe accuracy of the diagnosis increases with the addi-
ion of imaging and invasive testing. Recording the date
nd method used to confirm the clinical impression can be
dded in parentheses after the CEAP recording as follows:
ull form: C2,4a,5, S Ep As, p Pr2,3,18 (Level 2, Feb 8, 2010)
asic form: C5, S EpAs pPr (Level 2; Feb 8, 2010)
The main purpose of using the CEAP classification in
atients with CVD is to distinguish primary venous disease
rom congenital varicosity and, most importantly, from
econdary, post-thrombotic venous insufficiency.53 Evalu-
tion and treatment of the three conditions are distinctly
ifferent.
UTCOME ASSESSMENT
Outcome assessment of therapy of varicose veins and
ore advanced CVD includes standardized objective crite-
ia that reflect patient symptoms, characteristic signs, and
bjective measures of functional and disease-specific
OL.104
eneric QOL instruments
Generic QOL measures allow comparison with popu-
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May Supplement 201116S Gloviczki et alof any ill effects of treatment. Generic and disease-specific
QOL measures are usually complementary and should be
used together. Of the generic QOL instruments the Short
Form 36-Item Health Survey (SF-36) has been used with
success for assessment of global well-being of patients with
varicose veins.105,106
Venous disease–specific QOL instruments
Disease-specific QOL measurements are sensitive to
the beneficial effects of treatment. Different disease-
specific, patient-generated QOL tools and patient-reported
outcomes (PROs) have been popular in venous disease
reporting.107,108 The most frequently used validated ve-
nous disease–specific instruments include the Venous In-
sufficiency Epidemiologic and Economic Study of Quality-
of-Life (VEINES-QOL/Sym) questionnaire scale, the
Chronic Venous Insufficiency Questionnaire (CIVIQ), the
Aberdeen Varicose Vein Questionnaire (AVVQ), and
the Charing Cross Venous Ulceration Questionnaire
(CXVUQ).2,109-113
The VEINES instrument consists of 35 items in two
categories that generate two summary scores.109 The
VEINES-QOL questionnaire comprises 25 items that
study the effect of disease on QOL, and the VEINES
symptom questionnaire (VEINES-Sym) has 10 items that
measure symptoms. The focus of VEINES is on physical
symptoms rather than psychologic and social aspects.
The CIVIQ 2 is a revision of an instrument developed
to measure physical, psychologic, social, and pain fac-
tors.113 The revised version gives equal weight to each
category, with 20 questions that provide a global score.3
CIVIQ has been used in studies3,4 and proved to be a valid
QOL measurement.
The AVVQ is a 13-question survey addressing all ele-
ments of varicose vein disease. Physical symptoms and
social issues, including pain, ankle edema, ulcers, compres-
sion therapy use, and effect on daily activities, are examined
in addition to cosmesis issues. The questionnaire is scored
from 0 (no effect from varicose veins) to 100 (severe
effect).114,115
The CXVUQ was developed to provide a QOL mea-
sure for patients with venous ulcers. It provides a consistent
measure of patient-reported QOL in venous ulcers regard-
less of the treatment selected. Combining it with a generic
measurement instrument may provide valuable information
on the progression of ulcers and on the available treatment
measures.3
Physician-generated measurement tools
The physician-generated measurement tools include
the CEAP classification,76,77 which, as discussed previ-
ously, is an accurate description of signs and symptoms.
However, the instrument contains too many static ele-
ments, especially in classes C4 and C5, and is not partic-
ularly suitable for an assessment of improvement after
therapy.116
The VCSS was introduced by Rutherford et al104 and
has been used successfully in several studies to evaluate phanges in signs and symptoms over time and to quantify
utcomes.108,116-121 The VCSS is based on physician as-
essment of nine clinical signs or symptoms of CVD, in-
luding pain, presence of varicose veins, edema, signs of
VI, and venous ulcers. Compliance with compression
herapy is also assessed. The VCSS correlates well with the
EAP score and with ultrasonographic assessment of the
everity of venous valvular incompetence or obstruc-
ion.113,121-126
A revised VCSS (Table IV) has been developed recently
o clarify ambiguities, update terminology, and simplify
pplication of the first version.78 It now incorporates the
mportant language of the PRO assessment tools. The
resumption of venous origin is intended for all clinical
escriptors, and each limb is considered and scored sepa-
ately. These revisions are currently being validated in a
ulticenter field test.
The strength of the VCSS is in its evaluative properties
n identifying subtle intrasubject changes over time after an
ntervention.122,123 An evaluation of each VCSS compo-
ent allows outcome analysis on many levels, including
echnical, patient-reported, and clinical outcomes. In this
ense, the revised VCSS is unique among clinical outcome
ssessments and PROs. Although it is administered by a
hysician, components such as pain are scored by patient
esponses to subjective questions.78
To assess the benefit of a therapy, primary clinical
utcome standards are usually combined with a secondary
urrogate outcome assessment.124 Recommended report-
ng standards and outcome assessment for endovenous
blation have recently been published in a joint statement
f the AVF and the Society of Interventional Radiology.124
Clinical outcomes. Clinical outcome studies evaluate
he results of procedures on patient-focused outcomes,
ncluding symptom improvement, recurrence of varicosity,
ealing or recurrence of skin ulcers, improvement in the
hronic, progressive symptoms of CVD, improved QOL,
nd cosmetic improvement.124
Relief of symptoms. To report improvement in
ymptoms of CVD, we recommend the use of the revised
CSS in daily clinical practice.78 For research and publica-
ions to report outcomes, one of the validated, disease-
pecific QOL instruments should be added, such as
EINES-QOL/Sym questionnaire scale, CIVIQ-2, the
VVQ, or the CXVUQ score in patients with advanced
enous disease.2,3,109-113 A validated Likert pain scale can
lso be used, although most QOL questionnaires assess
ain and discomfort.
Disease severity. We recommend using the basic
EAP clinical classification along with the revised VCSS in
outine clinical practice. The revised VCSS is the best
urrently available instrument to quantify improvement
nd assess changes in the severity of CVD during follow-up
short-term, 1 year, midterm, 1-3 years, long term, 3
ears; Table IV).108 For research purposes, the complete
EAP classification should be used in addition to evalua-
ion of QOL after treatment to help to assess the patient’s
erception of the burden of the disease. A general QOL
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Volume 53, Number 16S Gloviczki et al 17Sinstrument, such as the SF-36, and one of the disease-
specific QOL instruments (eg, VEINES, CIVIQ, Ab-
erdeen) should both be used for this purpose.
Cosmetic results. Assessment of recurrent or residual
varicose veins continues to be a challenge, and there are
significant differences between physician assessments and
patient-reported results. Patient satisfaction is directly re-
lated to the disappearance of the treated unsightly varicose
veins. Photographing the treated areas is encouraged to
assess late results on varicose vein recurrence and the status
of skin changes. The Recurrent Varicose Veins After Sur-
gery (REVAS) classification125 is a descriptive evaluation of
recurrent and residual varicosities based on the physician’s
assessment, and we suggest its use, although further mod-
ification of the assessment is warranted.
Surrogate outcomes
Surrogate outcomes assess specific technical questions
about a particular therapy. Surrogate outcomes may in-
clude patency of the ablated saphenous or perforating vein,
patency of a venous stent, or hemodynamic results after
interventions. These should be used with care when evalu-
ating the clinical benefit of an intervention.124
Anatomic success. Patency of an ablated vein and the
length of the patent or obstructed segment of the vein, as
confirmed with duplex scanning, should be reported when
assessing anatomic success. Postprocedural duplex scan-
ning 1 month, at 1 year, at 1 to 3 years, and 3 years is
important to define periprocedural, early, midterm, and
late failures. Timing of the study is important because
saphenous patency after ablation on a periprocedural du-
plex image (3 days) indicates technical failure, whereas
late patency after early occlusion suggests recanalization.
The type of recurrence on late duplex scanning should also
be documented, because recanalization of a previously
occluded axial vein should be distinguished from neovas-
cularization, which implies the presence of multiple small
tortuous connections between the saphenous stump or the
femoral vein and a residual saphenous vein or its
tributaries.124
Hemodynamic success. The presence or absence of
recurrent reflux in treated incompetent veins should be
documented by duplex scanning, because this represents
technical failure or success of the procedure.126 Changes in
venous hemodynamics of the limb can also be documented
by changes in plethysmographic findings before and after
therapy; hemodynamic results frequently correlate with
clinical outcome.95,127
Safety
The safety of any procedure used for treatment of
varicose veins or more advanced CVD needs to be estab-
lished, and the procedurally related early adverse effects
(30 days) and late complications should be documented.
Table V defines minor and major complications for report-
ing purposes.124 gREATMENT
ndications
Most patients who seek treatment for varicose veins
ave symptoms of aching, throbbing, feeling of a heavy leg,
atigue, cramps, pruritus, restless leg, ankle swelling, and
enderness or pain along bulging varicose veins. Some will
ave history of thrombophlebitis or bleeding from superfi-
ial varicose veins or have signs of more advanced CVD,
uch as edema, skin changes, including lipodermatosclero-
is, eczema, pigmentation, atrophie blanche, corona phle-
ectatica, and healed or active ulceration. Less frequently,
he veins are of cosmetic concern only.
edical treatment
Venoactive drugs have been available for treatment of
ymptoms of varicose veins and more advanced forms of
VD for decades, and they have also been used to decrease
nkle swelling and accelerate ulcer healing.128 Many com-
ounds have been tried with varying success, but the most
romising drugs include saponins, such as the horse chest-
ut seed extract (aescin)129; gamma-benzopyrenes (fla-
onoids), such as rutosides, diosmin, and hesperidin; the
icronized purified flavonoid fraction (MPFF),130 and
ther plant extracts such as French maritime pine bark
xtract. Synthetic products include calcium dobesilate, naf-
azone, and benzarone.131
The principle for the use of venoactive drugs has been
o improve venous tone and capillary permeability, al-
hough a precise mechanism of action of most of these
rugs is unknown. Flavonoids appear to affect leukocytes
nd the endothelium by modifying the degree of inflamma-
ion and reducing edema.56
A recent Cochrane review of 110 publications selected
4 well-documented studies for analysis.132 The meta-
nalysis found that there appeared to be an effect on edema
nd on restless leg syndrome. Diosmin, hesperidin, and
PFF have been the most effective venoactive drugs. Cal-
ium dobesilate reduced cramps and restless legs. Diosmin
nd hesperidin helped healing of trophic skin changes and
ere useful in treatment of cramps and swelling. Rutosides
ecreased venous edema. This meta-analysis, however,
oncluded that there is insufficient evidence to support the
able V. Definition of complications
inor complications
No therapy, no consequence
Nominal therapy, no consequence; includes overnight
admission for observation only
ajor complications
Requires therapy, minor hospitalization (48 h)
Requires major therapy, unplanned increase in level of care,
prolonged hospitalization (48 h)
Permanent adverse sequelae
Death
dapted from Kundu et al.124 Used with permission.lobal use of venoactive drugs in the treatment of CVD.132
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May Supplement 201118S Gloviczki et alHorse chestnut seed extract. A separate Cochrane
review of 17 randomized controlled trials (RCTs) found
that horse chestnut seed extract (aescin) was effective to
decrease edema, pain, and itching.129
Pentoxifylline. The effect of pentoxifylline on ulcer
healing was investigated in an RCT by Dale et al.133 In a
double-blind, placebo-controlled trial, complete healing of
venous ulcers was observed in 64% of patients receiving
pentoxifylline and in 53% of the patients receiving placebo.
However, the difference was not statistically significant.
In another RCT, Falanga et al134 investigated the effect
of pentoxifylline on ulcer healing in 133 patients. Patients
who were given 800 mg of pentoxifylline three times a day
healed faster than those receiving placebo (P  .043). The
median time to complete healing was 100, 83, and 71 days
for placebo, pentoxifylline (400 mg), and pentoxifylline
(800 mg) three times a day, respectively. A higher dose of
pentoxifylline (800 mg three times a day) was more effec-
tive than the lower dose, although the higher dose had
more significant gastrointestinal upset. The study con-
cluded that pentoxifylline is effective in accelerating healing
of leg ulcers.
In a more recent RCT, evidence to add pentoxifylline
to a regimen of high-compression therapy to increase the
chances of wound healing was of moderate quality.135
Pentoxifylline increased the proportion of ulcer healing
compared with placebo, although this finding was only
statistically significant (P  .046) when a secondary ad-
justed analysis was conducted. Pentoxifylline in an oral dose
of 400 mg three times daily is suggested to patients with
venous ulcers in addition to local care, compression gar-
ment, or intermittent compression pump (ICP) in the
venous guidelines of the American College of Chest Physi-
cians (ACCP; GRADE 2B).136
Diosmin and hesperidin. The effect of a combination
of flavonoid drugs, diosmin, and hesperidin, in the form of
MPFF, in addition to compression therapy, was evaluated
Guideline 7. Outcome assessment
Guideline
No. 7. Outcome assessment
7.1 We recommend that the revised Venous Clinical
assessment of clinical outcome after therapy for
advanced chronic venous disease.
7.2 We recommend that quality-of-life assessment is p
disease-specific instrument to evaluate patient-r
the severity of chronic venous disease.
7.3 We recommend duplex scanning for follow-up of
procedures who have symptoms or recurrence
7.4 We recommend reporting procedure-related min
complications after therapy.on ulcer healing and symptoms of CVD in an RCT by wuilhou et al.137 Although the overall effect of the drug
hen combined with compression therapy, was weak,
mong patients with ulcers measuring10 cm, more ulcers
ealed in the MPFF group than in the placebo group (32%
s 13%; P  .028) with a shorter duration of healing (P 
037). Sensation of heavy leg was less in patients treated
ith MPFF (P  .030).
A meta-analysis of five RCTs that included 723 patients
ith venous ulcers was reported by Coleridge-Smith et
l.130 The study found that at 6 months, the chance of
ealing an ulcer was 32% better in patients treated with
djunctive MPFF than in those managed by conventional
herapy alone (relative risk reduction, 32%; 95% CI, 3%-
0%). These results confirm that venous ulcer healing is
ccelerated by MPFF treatment. For patients with persis-
ent venous ulcers, flavonoids, in the form of MPFF given
rally or sulodexide administered intramuscularly and then
rally, are suggested in the ACCP guidelines (GRADE
B).136 The SVS/AVF Guideline Committee also suggests
hat MPFF or pentoxifylline be used for patients with
enous ulcers as an adjuvant therapy to compression to
ccelerate ulcer healing (GRADE 2B).
ompression treatment
Compression therapy is the basic and most frequently
sed treatment of varicose veins, venous edema, skin
hanges, and ulcerations. Compression is recommended to
ecrease ambulatory venous hypertension to patients with
VD in addition to lifestyle modifications that include
eight loss, exercise, and elevation of the legs during the
ay whenever possible.
The different forms of ambulatory compression tech-
iques and devices include elastic compression stockings,
aste gauze boots (Unna boot), multilayer elastic wraps,
ressings, elastic and nonelastic bandages, and nonelastic
arments. Pneumatic compression devices (such as an
CP), applied primarily at night, are also used in patients
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Volume 53, Number 16S Gloviczki et al 19Sof compression treatment is to compensate for the in-
creased ambulatory venous hypertension. Pressures to
compress the superficial veins in supine patients range from
20 to 25 mm Hg. When upright, pressures of 35 to 40 mm
Hg have been shown to narrow the superficial veins, and
pressures 60 mm Hg are needed to occlude them.139
Varicose veins (CEAP class C2). Reported case series
of patients treated with elastic stockings frequently in-
cluded the whole spectrum of patients with CVD (CEAP
class C0-C6). Treatment with 30 to 40 mm Hg compres-
sion stockings in 112 patients (82% with varicose veins, 52%
with edema, and 7% with healed or active ulcers) resulted in
marked improvement in pain, swelling, skin pigmentation,
activity, and well-being at 16 months after initiation of
therapy, with compliance of 70%.140
A large systematic review of compression hosiery for
uncomplicated simple varicose veins was recently published
by Palfreyman and Michaels.34 They analyzed data of 11
prospective RCTs or systematic reviews, 12 nonrandom-
ized studies, and 2 guidelines. Although compression im-
proved symptoms, the study concluded that evidence is
lacking to support compression garments to decrease pro-
gression or to prevent recurrence of varicose veins after
treatment. However, these results could have been con-
founded by the high number of noncompliant patients
included in these studies.34
The level of compression for patients with class C2
disease is also disputed. A meta-analysis by Amsler and
Blattler141 of 11 RCTs suggested that in healthy patients,
in those with C1 to C3 disease, and in those after varicose
vein surgery, medium compression stockings (20 mm
Hg) may add no benefit over that obtained with a compres-
sion of between 10 and 15 mm Hg.
Until further data on appropriate tension of elastic
garments are available, for patients with simple varicose
veins (class C2), the SVS/AVF Guideline Committee sug-
gests graded prescription stockings with an ankle pressure
of 20 to 30 mm Hg (GRADE 2C). The most common
length recommended is knee-high stockings, although
thigh-high stockings and pantyhose are also available and
Guideline 8. Medical treatment
Guideline
No. 8. Medical treatment
8.1 We suggest venoactive drugs (diosmin, hesperidin, ru
purified flavonoid fraction, or horse chestnut seed
with pain and swelling due to chronic venous disea
drugs are available.
8.2 We suggest using pentoxifylline or micronized purifie
available, in combination with compression, to accmay be appropriate for many patients. Skin breakdown and trank necrosis after incorrectly measured or applied gar-
ents have been reported.142 The Committee recom-
ends that only those with the necessary skills and training
rescribe stockings for patients with venous disease.
The efficacy of conservative vs surgical treatment for
aricose veins was studied in an RCT by Michaels et al.143
he Randomised Clinical Trial, Observational Study and
ssessment of Cost-Effectiveness of the Treatment of Var-
cose Veins (REACTIV) trial randomized 246 patients with
imple varicose veins (class C2) to conservative manage-
ent or surgery. Conservative treatment included lifestyle
dvice relating to exercise, leg elevation, management of
eight and diet, and the use of compression hosiery. In the
urgical arm, patients received the same lifestyle advice but
lso underwent high ligation, stripping, and phlebecto-
ies. In the first 2 years after treatment, there was a
ignificant QOL benefit for surgery of 0.083 quality-
djusted life-years (QALY; 95% CI, 0.005-0.16 QALY)
ased on the SF-6D score (derived from scores on six
omains of the SF-36) and 0.13 QALY (95% CI, 0.016-
.25 QALY) based on the EQ-5D score (a five-dimension
escriptive system of health-related QOL). Considerable
enefits were also seen in symptomatic and anatomic mea-
ures. The authors concluded that surgery provides more
ymptomatic relief and improvements in QOL than conserva-
ive management with compression hosiery and lifestyle mod-
fications in patients with uncomplicated varicose veins.
The cost-effectiveness of conservative vs surgical ther-
py or sclerotherapy in patients with varicose veins was also
tudied in the REACTIV trial.144 Cost-effectiveness analy-
is showed that surgery was significantly more cost-effective
han both sclerotherapy and conservative management;
clerotherapy was less cost-effective than surgery but was
till significantly more cost-effective than conservative
reatment.
The need for a period of compression treatment before
ny intervention for simple varicose veins has been surrounded
y controversy. Although third-party payers often require a
rial of compression stockings, there is virtually no scientific
vidence to support such a policy when saphenous ablation
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May Supplement 201120S Gloviczki et alcost-effective, a fact supported by data of the REACTIV
trial. In addition, some patients, such as the obese or the
elderly, may have difficulties applying an elastic stock-
ings.138 One study of predominantly elderly (mean age, 72
years) women with CVD found that 15% could not apply
elastic stockings and 26% needed considerable help to do
so.145 On the basis of the available evidence, the Guideline
Committee recommends against compression therapy be-
ing considered the primary treatment of symptomatic var-
icose veins (class C2) in those patients who are candidates
for saphenous vein ablation (GRADE 1B).
CVI (CEAP classes C3-C6). Compression therapy
remains the standard of care for patients with advanced
CVD and venous ulcers (class C3-C6). Compression ther-
apy improves calf muscle pump function and decreases
reflux in vein segments in patients with CVI.146,147 In
patients with venous ulcers, graded compression is effective
as the primary treatment to aid healing of venous ulceration
and as adjuvant therapy to interventions to prevent recur-
rence of venous ulcers.148
Compliance with compression therapy is important. In
a cohort study by Mayberry et al,148 results of venous ulcer
treatment in 113 patients treated over 15 years were re-
ported. Ulcer healing with local care and compression
averaged 5.3 months, and was 97% in compliant patients
and 55% in noncompliant patients (P  .0001). Ulcer
recurrence was 16% in compliant patients and 100% in
noncompliant patients.
A systematic review of 24 RCTs on compression treat-
ment on venous ulcers by Fletcher et al36 concluded that
compression treatment improves the healing of ulcers com-
pared with no compression149 and that high compression is
more effective than low compression.150 The authors
found no evidence that one form of compression treatment
is better than another, although a previously published
single-center experience suggested that low-stretch inelas-
tic bandages were more effective in reducing venous reflux
than elastic bandages.151 The ACCP guidelines suggest the
use of an ICP in addition to a compression garment and
local care for treatment of recalcitrant ulcers.136
A recent meta-analysis by Amsler et al152 examined data
of 692 ulcer patients in eight RCTs and found that ulcer
healing was faster, with an average of 3 weeks, with stock-
ings than with bandages (P  .0002). Pain, examined in
three studies, was also significantly less with stockings than
with bandages (P  .0001).
Another systematic review by Partsch et al153 confirmed
(GRADE 1A) that compression bandaging promotes healing
of venous ulcers and that strong-compression hosiery (30 to
40 mm Hg) is more effective than medium- or low-compres-
sion stockings (GRADE 1B). This study observed GRADE
1A evidence that 30 to 40 mm Hg compression hosiery
prevents recurrence of ulceration after healing. A recent evi-
dence summary on ulcers by Coleridge-Smith154 supported
these recommendations.
An RCT by Milic et al155 compared treatment with
tubular compression (35 mm Hg) vs compression ban-
dages (25 mm Hg) in 138 patients with extensive venous Clceration (ulceration surface, 20-210 cm2; duration, 7
onths-28 years). The authors observed a healing rate of
3% in the treatment group vs 51% in the control group
P  .001). The recurrence rate at 12 months was 24% in
he treatment group and 53% in the control group (P 
05). After additional compression treatment with the same
reatment protocol, all 16 recurrent ulcers in the treatment
roup healed. In the control group, the healing rate of
ecurrent ulcers was 89%. This study suggests that for
xtensive and long-standing venous ulceration, multilayer
ubular compression therapy improves healing and de-
reases but does not prevent ulcer recurrence.
The Effect of Surgery and Compression on Healing
nd Recurrence (ESCHAR) study156,157 randomized 500
atients with leg ulcers to compression treatment alone or
ompression combined with superficial venous surgery.
ompression consisted of multilayer compression bandag-
ng, followed by class 2 (medium compression, 18-24 mm
g, British Standard158) below-knee stockings. Superficial
enous surgery included saphenous vein ablation with high
igation and stripping (HL/S) as well as avulsion of varicose
eins of the calf. General anesthesia could not be used in
5% of the patients, and in these, high saphenous vein
igation alone was performed.
Compression treatment alone was as effective as com-
ression with surgery to heal venous ulcers (65% vs 65%;
azard ratio, 0.84; 95% CI, 0.77-1.24; P  .85), but
2-month ulcer recurrence rates were reduced in the com-
ression with surgery group vs those with compression
lone (12% vs 28%; hazard ratio,2.76; 95% CI,1.78 to
4.27; P .0001). The difference in ulcer recurrence rates
ersisted between the two groups at 4 years.159 A weakness
f the trial was that there was no surgical arm without
ompression. This was unfortunate, because there is some
vidence that saphenous vein disconnection improves ve-
ous function and heals venous ulcers, even without com-
ression bandaging, if the deep veins are normal.160
A meta-analysis and Cochrane Collaboration review of
2 RCTs by Palfreyman et al42,161 searched for evidence of
ffectiveness of dressings applied to venous leg ulcers in
ddition to compression. The authors concluded that there
s no evidence that hydrocolloid or other dressings beneath
ompression are more effective than compression alone.
On the basis of high-quality clinical evidence, the
uideline Committee recommends compression therapy
or patients with CVI (class C3-C6), including those with
eg ulcers. Compression therapy is now considered the
rimary therapy to aid in healing venous ulcers (GRADE
B) and the adjuvant therapy to superficial vein ablation to
revent ulcer recurrence (GRADE 1A).
pen venous surgery
Open surgical treatment of varicose veins with ligation
nd stripping of the GSV or SSV, combined with excision
f large varicose veins, has been the standard of care of
aricose vein treatment for more than a century. Invagina-
ion stripping was first attempted by Keller162 in 1905,
harles Mayo in 1906163 used an external stripper to
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Volume 53, Number 16S Gloviczki et al 21Sremove the saphenous veins, and Babcock in 1907164
introduced intraluminal stripping from the ankle to the
groin. High ligation and ankle-to-groin stripping using a
metal or, later, a disposable Codman or Myers stripper has
become the technique of choice to remove the saphenous
vein. Recognition of frequent saphenous nerve injury dur-
ing ankle-to-groin stripping and a better understanding of
the venous hemodynamics changed the technique to a
limited, groin-to-knee stripping.165
The invagination technique using a silk thread was
perfected by Van Der Stricht166 and using the Myers strip-
per, without the acorn-shaped head, by Fullarton and Cal-
vert,167 while perforate invaginate (PIN) stripping was
introduced by Oesch168 and perfected in the United States
by Goren and Yellin.169 Varicose vein excision performed
from multiple larger skin incisions170,171 was also aban-
doned, and ambulatory hook phlebectomy172,173 and
powered phlebectomy174-176 have been adopted.
During the past decade, endovenous thermal ablation
has largely replaced the classic ligation and stripping oper-
ation, and open surgery for saphenous incompetence is
performed much less frequently in the United States. Indi-
cations for ligation and stripping have been restricted to
patients with large dilated and tortuous saphenous vein
located immediately under the skin or to those with aneu-
rysmal enlargement at the SFJ. Because of previous throm-
bophlebitis of the GSV or SSV, percutaneous placement of
the laser fiber or radiofrequency (RF) catheter may not be
possible, and open techniques have to be used for removal
of the vein.
It is important to note, however, that the technique of
open surgery has also changed substantially in recent years,
and today a much less invasive procedure is performed to
treat the incompetent saphenous veins than at anytime
before. The groin incision is small, the incision at the knee
for inversion stripping is either a puncture wound (PIN
stripping) or a small stab wound, and the operation is
performed under local tumescent anesthesia with increas-
Guideline 9. Compression treatment
Guideline
No. 9. Compression treatmen
9.1 We suggest compression therapy using moderate pr
patients with symptomatic varicose veins.
9.2 We recommend against compression therapy as the
symptomatic varicose veins in patients who are ca
ablation.
9.3 We recommend compression as the primary therape
venous ulcers.
9.4 We recommend compression as an adjuvant treatme
for the prevention of ulcer recurrence.ing frequency.177 Although endothermal ablations are fa- tored in the United States, in many countries conventional
urgery remains the standard of care of patients with vari-
ose veins.178
High ligation, division, and stripping of the
SV. The term high ligation and division implies ligation
nd division of the GSV at its confluence with the common
emoral vein, including ligation and division of all upper
SV tributaries.51 Partial or complete preservation of the
pper GSV tributaries, when the GSV is ligated, stripped,
r ablated, must therefore be clearly stated. The term
tripping means removal of a long vein segment, usually of
he saphenous vein, by means of a device.51
The SFJ is dissected through a 3- to 4-cm-long oblique
ncision made in the groin crease just lateral to the femoral
rtery. The cosmetic appearance of the scar of such an
ncision is excellent. The SFJ is dissected bluntly and
harply, minimizing injury to the surrounding lymphatic
issue to avoid lymphatic leak or lymphedema. The anterior
all of the common femoral vein is always visualized to
nsure accurate ligation of the SFJ. All tributaries are li-
ated and divided, preferably to the secondary branches,177
lthough firm evidence to support the need for this is not
vailable. During dissection of the SFJ, the external puden-
al artery is carefully preserved. Flush ligation of the saphe-
ous vein is performed by double-ligating the vein with
onabsorbable suture close to the SFJ. It is important to
void narrowing the femoral vein but equally important to
inimize chances for a cul-de-sac in the saphenous vein
tump.
To perform stripping, a flexible Codman stripper is
ften used for invagination stripping, without the remov-
ble acorn. The saphenous vein is tied to the tip of the
tripper, and the vein is inverted into its lumen as the
tripper is pulled down through a small incision made
elow the knee. Alternatively, an Oesch PIN stripper can be
sed.168,169 Saphenous stripping below the knee is rarely
erformed today because of an increased incidence of re-
orted saphenous nerve injury.165 To decrease bleeding in
GRADE of
recommendation
Level of
evidence
1. Strong A. High
quality
2. Weak B. Moderate
quality
C. Low or very
low quality
(20 to 30 mm Hg) for 2 C
ry treatment of
tes for saphenous vein
1 B
odality for healing 1 B
superficial vein ablation 1 At
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thetic solution.
The operation is usually completed with a miniphlebec-
tomy to remove the bulging varicose veins through a small
stab wound. The incisions are then infiltrated with tumes-
cent solutions, the groin incision is closed in layers with
nonadsorbable sutures, and the stab wounds are closed
with sterile adhesive strips. The extremity is bandaged with
an elastic bandage to decrease the risk of bleeding and to
decrease swelling and pain. The operation is an outpatient
procedure.
High ligation, division, and stripping of the SSV.
Complete stripping of the SSV is rarely performed today
because of possible injury to the sural nerve, but ligation of
the SSV through a small transverse incision in the popliteal
crease can be performed together with a limited invagina-
tion stripping of the vein to the mid calf, using the same
technique described for GSV stripping. The safest tech-
nique to identify the SSV is intraoperative duplex scanning.
There is no evidence that flush ligation is better than simple
ligation of the vein when performed at a location closer to
the skin, usually right in the knee crease. We recommend
ligation of the SSV at this level, about 3 to 5 cm distal to the
saphenopopliteal junction, since this can be performed
through a very small skin incision and it avoids the need for
deep dissection in the popliteal fossa, with the potential for
associated wound complications or nerve injury.
Cryostripping of the GSV. To decrease hemorrhage
within the saphenous tunnel and avoid any incision placed
at the level of the knee, the technique of cryostripping has
been suggested by some investigators.179 Cryostripping is
an alternative method to invagination stripping.180 The
technique is new in the United States and has not been fully
evaluated.
For cryostripping, a cryosurgical system (Erbokryo CA,
ERBE Elektromedizin GmbH, Tübingen, Germany),
powered by liquid nitrogen, is used. After high ligation is
completed, the cryoprobe is inserted into the saphenous
vein and passed down to the level of the knee. As soon as
the probe tip reaches the desired segment of the GSV,
freezing is initiated. After the freezing cycle is maintained
for a couple of seconds, the GSV is invaginated with an
upward tug and is stripped toward the groin.
Phlebectomy
Ambulatory phlebectomy. Ambulatory phlebectomy
(stab or hook phlebectomy or miniphlebectomy) includes
removal or avulsion of varicose veins through small stab
wounds, made with a No. 11 Beaver blade or a 15° oph-
thalmologic blade, or through the puncture hole made
with a larger, 19-gauge needle. Avulsion of the varicose
veins is performed with hooks or forceps.172,173 The
most widely known hooks are Müller, Oesch, Tretbar,
Ramelet, Varady, and Dortu-Martimbeau phlebectomy
hooks.172,173,181 The veins are marked before surgery on
the patient’s skin with a marker, with the patient standing.
The operation is usually performed under tumescent local
anesthesia, using a solution of 445 mL of 0.9% saline, 50 dL of 1% lidocaine with 1:100,000 epinephrine, and 5 mL
f 8.4% sodium bicarbonate.181
A rigid cannula with a light source can be used to inject
he tumescent solution and also to transilluminate the
ubcutaneous tissues under the varicose veins.182 Injection
f the tumescent solution can be performed using a large
yringe or a Klein infiltration pump.181,183 Digital com-
ression is applied immediately, and infiltration of the
ound with tumescent solution also provides good hemo-
tasis. The skin incisions are usually approximated with
terile adhesive strips, and compression is applied to the
xtremity from foot to groin with an elastic compression
andage or compression stocking.
Powered phlebectomy. Transilluminated powered phle-
ectomy (TIPP; Trivex, InaVein, Lexington, Mass), an
lternative technique for the removal of varicose veins, is
specially useful for the removal of larger clusters of vari-
osities.184,185 The potential advantages of TIPP include a
ecrease in the number of incisions and much faster re-
oval of a large amount of varicose vein tissue. Just as for
mbulatory phlebectomy, TIPP is often combined with
aphenous vein ablation procedures or stripping and liga-
ion to eliminate the source of the reflux underlying a
aricose venous cluster formation. Instrumentation in-
ludes a central power unit with controls for irrigation
ump and resection oscillation speeds, an illuminator hand
iece that connects to the control unit using a fiber optic
able and provides high-intensity light for transillumination
nd delivery of tumescence irrigation, and a resector hand
iece that has 4.5-mm and 5.5-mm options.
General, epidural, or spinal anesthesia can be used,
epending on patient preference, while local tumescence
nesthesia and conscious sedation may be options for lim-
ted varicosities in selected patients. In the procedure, TIPP
nstruments are introduced through tiny incisions. The
lluminator produces transilluminated visualization of the
eins to be removed, allows delivery of tumescent anes-
hetic solution, and performs hydrodissection. Through
egmental counterincisions under direct visualization, the
esector is positioned directly on the varicosity, and with
owered endoscopic dissection, varicosities are mobilized
ree and then suctioned out of the leg. The addition of small
.5-mm punch incisions allows for blood that collects in
he vein tract to be flushed out with further tumescent
nesthetic fluid.184-186
Preservation of the GSV. Preservation of the saphe-
ous vein and treatment of varicose tributaries by phlebec-
omy has been advocated by Francesci in the CHIVA (cure
onservatrice et hémodynamique de l’insuffisance veineuse en
mbulatiore [ambulatory conservative hemodynamic man-
gement of varicose veins]) technique186-189 and by Pitta-
uga in the ASVAL (ablation sélective des varices sous anes-
hésie locale [ie ambulatory selective varicose vein ablation
nder local anesthesia]) technique.126
The CHIVA technique. The CHIVA technique is a
emodynamic approach to varicose veins based on the
rinciples of preserving the saphenous vein and venous
rainage into the deep system.186,190 The goal of CHIVA
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Volume 53, Number 16S Gloviczki et al 23Sis to decrease the hydrostatic pressure in the saphenous
veins and tributaries by the ligations placed in specific areas
in the superficial venous system and to maintain the drain-
age function of the superficial veins, usually via a reversed
flow.186 It represents a systematic approach to varicose
veins rather than a single operative procedure.
Several anatomic patterns of reflux have been identi-
fied, each requiring a somewhat different operative strategy
based on the underlying anatomy, studied in utmost detail
with duplex scanning.188 A frequently used CHIVA tech-
nique presented in an RCT included proximal ligation of
the incompetent saphenous vein; ligation, division, and
avulsion of the incompetent varicose tributaries; and main-
taining patency of the saphenous trunk, the competent
saphenous tributaries, and saphenous venous drainage to
the deep system through the so-called reentry perfora-
tors.191 A recently published RCT presented further details
of the technique in six different types of varicosity.192
The ASVAL technique. Described by Pittaluga et
al,126 the ASVAL operation includes preservation of the
incompetent saphenous vein and stab phlebectomy of all
varicose tributaries. Most patients operated on with this
technique in one study had a less advanced stage of varicos-
ity (CEAP class C2) and presented with no symptoms in
33% and no trophic skin changes in 91%.126
Perioperative thrombosis prophylaxis. Selective
prophylaxis after risk assessment is warranted in patients
who undergo venous surgery. The risk of DVT is increased
in patients with thrombophilia, in those with a history of
DVT or thrombophlebitis, and in obese patients. Similarly
to the recently published ACCP guidelines,159 we recom-
mend, for patients who do not have additional thrombo-
embolic risk factors, that surgeons not routinely use specific
thromboprophylaxis other than early and frequent ambu-
lation (GRADE 2B). For those with additional thrombo-
embolic risk factors, we recommend thromboprophylaxis
with low-molecular-weight heparin, low-dose unfraction-
ated heparin, or fondaparinux (GRADE 1C).
Results of open venous surgery. Results of open
surgery have continued to improve during the past decades,
and HL/S of the GSV performed as an outpatient proce-
dure is a safe and effective operation. Surgical treatment is
superior to conservative management of varicose veins with
use of elastic garments. In the REACTIV trial,144 as dis-
cussed previously, results of surgery with compression
treatment were compared with results of compression treat-
ment alone in 246 patients with uncomplicated varicose
veins.143 Surgical treatment included flush ligation of sites
of reflux, stripping of the GSV, and multiple phlebecto-
mies. At 2 years, surgery provided more symptomatic relief,
better cosmetic results, and much-improved QOL over
conservative management.
Marked improvement in QOL after open surgery was
also demonstrated in an RCT by Rasmussen et al.177 In a
prospective cohort study, Mackenzie et al193 monitored
102 consecutive patients who underwent varicose vein
surgery. At 2 years after surgery, health-related QOL mark-
edly improved to baseline when assessed with the Aberdeen aaricose Vein Symptom Severity Score and the SF-36.
mprovement in QOL from varicose vein surgery has been
hown to be statistically significant and clinically meaning-
ul, matching the benefits observed after elective laparo-
copic cholecystectomy.194
Recovery after conventional high ligation and inversion
tripping with associated phlebectomies has been variable
n different reports. In a series of 112 procedures performed
n an office setting under locoregional anesthesia, using
igh ligation, PIN stripping, and hook phlebectomy, Go-
en and Yellin169 reported that all their patients resumed
ormal daily and sporting activities immediately after sur-
ery and none had major complications. There was fre-
uent bruising, but no tract hematomas, no nerve damage,
nd no DVTs were noted in this series. Follow-up of this
eries, however, was poor and the quality of evidence of
reatment efficacy was low.
In an RCT that compared high ligation, stripping, and
hlebectomy with RFA and phlebectomy, the open surgical
roup at 3 weeks had a 2.8% wound infection rate, 19.4% of
he patients had ecchymosis, 33.3% had hematoma, and
.6% had paresthesias.195 Most importantly, time to return
o normal activities averaged 3.89 days (95% CI, 2.67-5.12
ays; P  .02), only 46.9% of patients returned to routine
aily activities within 1 day, and the number of days to
eturn to work averaged 12.4 days (95% CI, 8.66-16.23
ays).
HL/S vs high ligation alone. HL/S of the GSV re-
uced the risk of reoperation by two-thirds at 5 years after
urgery in a prospective randomized study reported by
werryhouse et al.196 The authors randomized 133 legs of
00 patients to high ligation or HL/S. The need for
eoperation was 6% in patients who underwent HL/S vs
0% in those patients who underwent high ligation alone
P .02). The reason for this is that patients with only high
igation have recurrent reflux in the residual GSV, which
auses new symptoms and increases the risk of reoperation.
The effect of saphenous stump closure on outcome. In an
CT, Frings et al197 found more neovascularization in
atients who had the endothelium of the saphenous stump
xposed vs those who had the saphenous stump oversewn
ith a running nonabsorbable polypropylene suture. (Neo-
ascularization has been defined as the presence of multiple
ew small tortuous veins in anatomic proximity to a previ-
us venous intervention.51) No conclusion could be
eached, however, on the type of suture used to ligate the
tump. Neoreflux was the same after ligature with absorb-
ble suture vs nonabsorbable suture.
An RCT by Winterborn et al198 observed no difference
n varicose vein recurrence if a standard saphenofemoral
igation (transfixation and ligation using nonabsorbable
uture, with exposed endothelium of the stump) or a flush
aphenofemoral ligation (the stump was oversewn with a
unning polypropylene suture, with no endothelium ex-
osed) was used. At 2 years, the recurrence rate was 33% in
he standard group and 32% in the flush group (P  .90).
eovascularization was present in 22% in standard groupnd in 19% in the flush group (P  .57).
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May Supplement 201124S Gloviczki et alAnother RCT on 389 limbs by van Rij et al199 observed
that placement of a polytetrafluoroethylene (PTFE) patch
over the SFJ halved recurrence at 3 years compared with
controls and that a synthetic patch was an effective mechan-
ical suppressant of neovasculogenesis at the groin. These
findings were not confirmed, however, in a smaller RCT by
Winterborn and Earnshaw.200 This study randomized 40
legs to insertion or no insertion of a PTFE patch over the
ligated SFJ. The overall complication rate was 35% (11
legs), with no statistically significant difference between the
groups. By 2 years postoperatively, duplex imaging showed
neovascularization had developed at the SFJ in 4 of 16 legs
without a patch and in 5 of 16 legs with a patch (P  1.0).
We recommend double ligation of the SFJ with nonabsorb-
able suture (GRADE 1C), but we suggest against using a
PTFE patch to cover the saphenous stump (GRADE 2C).
Complications. Wound complications usually occur in
3% to 10% of patients,178,201 with reported wound infec-
tion rates as low as 1.5% and as high as 16%.202-204 An RCT
by Biswas et al205 evaluated the efficacy of the duration of
compression therapy in 300 postsurgical patients. The
study found no benefit in wearing compression stockings
for 1 week after uncomplicated HL/S of the GSV with
respect to postoperative pain, number of complications,
time to return to work, or patient satisfaction for up to 12
weeks after surgery.205
In a recent RCT that included 443 patients who under-
went groin surgery for varicose veins, the risk of wound
infections and wound-related complications was reduced
with use of a single dose of perioperative antibiotic prophy-
laxis.206 Wound outcomes were worse with higher body
mass index (OR, 0.92; 95% CI, 0.87-0.97; P  .005) and
with current smoking (OR, 0.5; 95% CI, 0.3-0.9; P 
.033).206
Nerve injury. Using conventional stripping tech-
niques, the incidence of saphenous nerve injury in one
study was 7% in patients who had stripping to the knee and
39% in those who had stripping to the ankle.165 Sural nerve
injury occurred at a rate of 2% to 4%. Common peroneal
nerve injury occurred in 4.7% in one series and in 6.7% in
another series in those patients who underwent SSV liga-
tion or stripping.207
Injury to the femoral artery and vein. Injury to the
femoral vein or artery during high ligation of the saphenous
vein is, fortunately, very rare. Consequences can be disas-
trous, because most are not recognized immediately,208
and a delay in treatment may result in massive DVT or even
loss of the limb from the severe arterial injury.
Thromboembolic complications. DVT and pulmonary
embolism (PE) are rare but occasionally serious complica-
tions of superficial vein surgery. In a prospective study, Van
Rij209 performed duplex scanning in 377 patients before
surgery and then at 2 to 4 weeks and at 6 to 12 months after
surgery. Acute DVT was detected in 20 patients (5.3%).
Eight were symptomatic and no PE was observed. Al-
though this series suggests an incidence of DVT that is
higher than previously believed, this complication had min-
imal short-term or long-term clinical significance. Of the c0 DVTs, 18 were confined to calf veins, and half of the
VTs had resolved without deep venous reflux at 1 year.
thers reported an incidence of 0.5% for DVT and 0.16%
or PE.201
Conventional stripping vs cryostripping. An RCT by
enyhei et al179 randomized 160 patients to high ligation,
ivision, and cryostripping vs conventional stripping. No
ifferences in QOL measures were noted by the SF-36
uestionnaire at 6 months between the two groups. Bruis-
ng was more frequent after conventional stripping (P 
01), but there was no difference in pain score or compli-
ations. Two patients from the conventional stripping
roup and six from the cryostripping group were excluded
rom analysis because of incomplete stripping. Experience
ith this technique in the United States is limited, and at
his time no recommendation is made.
Results of superficial vein surgery on ulcer healing
nd recurrence. High quality evidence indicates that su-
erficial vein surgery reduces ulcer recurrence. The
SCHAR study,156,157 as discussed earlier, randomized
00 patients with leg ulcers, who had isolated superficial
enous reflux or mixed superficial and deep reflux, to
ompression treatment alone or to compression combined
ith superficial venous surgery. Compression consisted of
ultilayer compression bandaging, followed by class 2
elow-knee stockings. Surgery included high ligation, divi-
ion, and saphenous stripping. Rates of healing at 24 weeks
ere similar in both groups (65% vs 65%; hazard ratio,
.84; 95% CI, 0.77-1.24; P  .85), but 12-month ulcer
ecurrence rates were reduced in the compression with
urgery group (12% vs 28%; hazard ratio, 2.76; 95% CI,
1.78 to 4.27; P  .0001). The difference in ulcer
ecurrence rates between the two groups at 4 years was
ignificant.157
Powered phlebectomy vs stab phlebectomy. A limited
umber of studies, both retrospective and prospective, have
een performed. Overall, reported complications after
IPP have varied considerably and include ecchymosis and
ematoma in 4.9% to 95%, paresthesias and nerve injury in
.5% to 39%, skin perforation in 1.2% to 5%, superficial
hlebitis in 2.4% to 13%, swelling in 5% to 17.5%, hyper-
igmentation in 1.2% to 3.3%, residual or recurrent vari-
ose veins in 9.1% to 21.2%, and DVT in 1%.174,210 In a
omparison between TIPP and stab phlebectomy, TIPP
evealed a difference in the number of incisions174 and in
he speed of the procedure.178,179 However, there was no
ifference in bruising, cellulitis, and numbness at 1 to 2
eeks; nerve injury, residual veins, cosmesis score, and
verall satisfaction at 6 weeks; and cosmesis or recurrence at
and 12 months. A learning curve to determine just how
ggressive the surgeon can be during the procedure to
liminate all veins while minimizing bruising and other
ocal complications has also been noted.211,212 These
eports, however, used an early-generation system,
igher oscillation speeds (800-1200 rpm), and minimal
umescence.
With a newer-generation system and technical modifi-
ations incorporating a lower oscillation frequency (300-
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tumescence with extensive flushing of residual hematoma
and residual venous tissue fragments, and an additional
tertiary subdermal tumescence phase, the results of pow-
ered phlebectomy have improved.213 The largest series214
using modified techniques included 339 patients with a
mean operative time of 19.7 minutes, and 60% of cases
involving 10 to 20 incisions. Discoloration of the skin was
noted in eight patients (2.3%), excessive or hypertrophic
scarring in two (0.6%), and cellulitis in one (0.3%). There
were no significant hematomas and no recurrent varicose
veins at 12 weeks in this series, and overall, 99.7% reported
good outcomes and satisfaction.
Although no published data clearly show any statisti-
cally significant advantage of TIPP over conventional phle-
bectomy except for fewer incisions, most published litera-
ture represents earlier-generation systems and techniques.
With the newer-generation system and modified technique
and learning curve adjustments, TIPP has become less
traumatic, which may decrease potential complications and
improve outcomes over those previously reported. Until
new trials are performed, any additional potential benefits
of TIPP have yet to be substantiated.
Results with preservation of the saphenous vein.Results
with CHIVA. Two RCTs188,191 compared standard treat-
ment (compression or high ligation, stripping, and phle-
bectomy) with CHIVA approaches with specific anatomic
patterns of reflux (types I and III shunts). For the specific
venous anatomy evaluated in these trials, such techniques
were better than compression in preventing ulcer recur-
rence188 and were at least equivalent to stripping of varicose
veins.191
In a single-center RCT, Zamboni et al188 used CHIVA
or compression to treat 47 legs with venous ulcers. At a
mean follow-up of 3 years, healing was 100% (median
healing time, 31 days) in the surgical group and 96%
(median healing time, 63 days) in the compression group
(P .02). The recurrence rate was 9% in the surgical group
and 38% in the compression group (P  .05). The study
excluded patients with post-thrombotic syndrome, deep
vein reflux or obstruction, or excessive ulcers (12 cm).
In a recent open-label, single-center RCT, Pares et
al192 randomized 501 patients with primary varicose veins
into three arms: CHIVA, stripping with clinic marking, and
stripping with duplex marking. The primary end point was
recurrence within 5 years, assessed clinically by indepen-
dent observers. Clinical outcomes in the CHIVA group
were better (44.3% cure, 24.6% improvement, 31.1% fail-
ure) than in the stripping with clinic marking (21.0% cure,
26.3% improvement, 52.7% failure) and stripping with
duplex marking (29.3% cure, 22.8% improvement, 47.9%
failure) groups. The OR between the stripping with clinic
marking and CHIVA groups, of recurrence at 5 years of
follow-up, was 2.64 (95% CI, 1.76-3.97; P  .001). The
OR of recurrence at 5 years between the stripping with
duplex marking and CHIVA group was 2.01 (95% CI,
1.34-3.00; P  .001). mAlthough the first two RCTs focused on a small group
f patients with varicose veins, the trial of Pares et al192
eserves credit for including the full spectrum of patients
ith primary varicose veins. CHIVA is a complex approach,
nd a high level of training and experience is needed to
ttain the results presented in this RCT. However, the
esults achieved by a few outstanding interventionists does
ot support offering this procedure to all practitioners.
lthough CHIVA has called attention to the importance
f directing surgical procedures toward the patient’s
enous anatomy and function, it still requires consider-
ble education of venous interventionists willing to learn
his approach.
Results with ASVAL. Good clinical results have been
eported with the ASVAL procedure in a select group of
atients. After 4 years of follow-up, no reflux or minimal
eflux (500 ms) was found in 66.3% of 303 limbs, and
ymptoms improved in 78% and varicose vein recurred in
nly 11.5%.126
Current selection criteria for the ASVAL procedure
nclude patients with mild CVD, with either a competent
erminal valve or segmental saphenous reflux, and no or
inimal symptoms. Most had a GSV diameter 8 mm or
SV diameter6 mm. Although promising in this group of
atients with largely cosmetic concerns, the technique is
ot generalizable and has not been evaluated in any com-
arative studies against well-validated surgical techniques
GRADE 2C).
Recurrent varicose veins. Recurrent varicose veins
fter surgical treatment are a serious problem, and many
atients require additional interventions. Surgery for recur-
ence represents a considerable proportion of the workload
f surgeons operating on varicose veins. The operations are
echnically more demanding and complicated than first-
ime operations.
Recurrent varicose veins after surgery (REVAS) have
een reported at rates ranging from 6.6% to 37% at 2
ears177,215,216 and up to 51% at 5 years.217-222 Most
tudies reported 2-year clinical recurrence rates of 20% to
7% after conventional or cryostripping, when residual or
ecurrent varicose veins noted by both the patient and the
urgeon were counted.216,220 In a 34-year follow-up study
f 125 limbs, Fischer et al221 noted ultrasonographic evi-
ence of saphenofemoral reflux in 75 limbs (60%). Allegra
t al219 noted a 5-year recurrence rate of 25% in a large
tudy that included 1326 patients. Despite technically
orrect surgery, confirmed with postoperative duplex
canning, recurrence at the SFJ occurred in 13%, at the
aphenopopliteal junction in 30%, and at both in 36%.
actors predicting recurrence were SSV reflux, perforat-
ng vein incompetence, and post-thrombotic deep vein
ncompetence.
A consensus document on REVAS found that the main
easons for recurrence after surgery were technical and
actical errors, neovascularization at the groin, and progres-
ion of the underlying disease.217 In a multicenter registry
hat included 199 limbs of 170 patients with REVAS, the
ost frequent sources of recurrent reflux were the SFJ
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May Supplement 201126S Gloviczki et al(47.2%), followed by leg perforators (54.7%), neovascular-
ization (20%), and technical failure (19%); both neovascu-
larization and technical failure occurred in 17%, and in 35%,
the cause was uncertain or unknown.215 In a study of 279
limbs with recurrent varicose veins at the groin, Geier et
al223 found a long residual saphenofemoral stump in about
two-thirds of cases, recurrences became apparent after a
mean time interval of 6.3 years, and symptoms occurred
after a mean of 8.5 years.
Evaluation. Treatment of symptomatic recurrent var-
icose veins should be performed after careful evaluation of
the patient with duplex scanning to assess the etiology,
source, type, and extent of recurrent varicose veins. Sites of
reflux at the SFJ or saphenopopliteal junction and at the
sites of clinically important perforating veins should be
searched. Duplex scanning is excellent in identifying resid-
ual saphenous stumps, but it has a sensitivity of 62% and a
positive predictive value of only 26% to identify correctly
the presence of neovascularization.224 Histologic examina-
tion is still the gold standard when trying to differentiate
between different types of groin recurrences. If perineal or
medial thigh varicosity suggests pelvic reflux, evaluation
with transvaginal ultrasonography may be used, although
the gonadal and pelvic veins are best evaluated with MR or
contrast venography.225,226
Techniques and results of treatment. Ambulatory
phlebectomy, sclerotherapy, or endovenous thermal abla-
tion of accessory saphenous or perforating veins can be
performed, depending on the source, location, and extent
of recurrence. Conventional open surgery usually involves
repeat disconnection of the SFJ combined with ambulatory
phlebectomy. The SEPS procedure to treat incompetent
perforating veins in patients with advanced disease (class
C5-C6) can be useful. Endovenous thermal ablation can
also be performed to treat persistent great, small, or acces-
sory saphenous veins or perforators, and foam sclerotherapy
has been used successfully, alone or with phlebectomy, to
treat recurrent varicose veins and perforating veins.227
Phlebectomy alone, without repeat ligation of the sa-
phenous stump, was studied by Pittaluga et al228 for treat-
ment of recurrent varicose veins in 473 limbs. After 3 years
of follow-up, those with phlebectomy alone and those with
phlebectomy and stump ligation had similar rates of free-
dom from inguinal reflux (90.8% vs 92.9%) and from
varicose repeat-recurrence (90.8% vs 91.9%), suggesting
that the increased complications of groin reoperations can
be avoided in some patients.
In a prospective nonrandomized trial, recurrent vari-
cosity was treated by van Groenendael et al229 in 149 limbs
with open surgery and in 67 with EVLA. Wound infections
(8% vs 0%; P .05) and paresthesias (27% vs 13%; P .05)
were more frequent in the surgery group, whereas the
EVLA group reported more perioperative pain or tightness
(17% vs 31%; P  .05). Hospital stay in the surgery group
was longer (P .05) as was the delay before resuming work
(7 vs 2 days; P  .0001). At 25 weeks of follow-up, repeat
recurrences were reported in 29% after surgery and in 19%
after EVLA (P .511). Similar results were reported by the wame authors in patients who underwent open surgery or
VLA for recurrent varicose veins of the SSV.230 These
onrandomized studies provide only low-quality evidence
hat EVLA, when possible to perform, results in lower
omplication rates and better socioeconomic outcome in
atients with recurrent varicose veins than open surgery.
Creton and Uhl227 treated 129 limbs with recurrent
aricose veins using foam sclerotherapy with 1% polido-
anol combined with surgical treatment. All patients had
hlebectomies, and 20 had repeat ligation of the saphenous
tumps. Foam sclerotherapy combined with surgery re-
ulted in 93% closure of the saphenous stumps and no
ecurrent varicose veins. Two patients had asymptomatic
VT. Another study, by O’Hare et al,231 found no differ-
nce in occlusion rate of primary and recurrent varicose
eins (75% vs 72%) at 6 months when treated with ultra-
onographically guided foam sclerotherapy.
ndovenous thermal ablations
Endovenous thermal ablation of the saphenous veins is
relatively new, minimally invasive percutaneous proce-
ure with several advantages over standard open sur-
ery.232 It requires local tumescent anesthesia and is an
utpatient procedure that can be performed in an office
etting. The procedure is done under ultrasonographic
uidance using percutaneous catheter placement; patients
omplain less of pain and discomfort and return to work
arlier than after open surgical procedures. Endovenous
hermal ablation includes EVLA and RFA (Table VI). A
hird technique that recently emerged includes the use of
uperheated steam, which destroys the endothelial layer
nd causes shrinkage of the collagen.233 Early clinical ap-
lication, as reported by Milleret et al,233 is promising, but
vailable data are not sufficient to include this technique in
ur report in more detail. EVLA and RFA are similar
echniques in many ways, so a discussion of concepts and
ata applying to both of these procedures is appropriate.
Occlusion (ablation) of the treated vein is achieved by
eat delivered into the vein through the percutaneously
laced laser fiber or an RF catheter. Endovenous thermal
blation causes a direct thermal injury to the vein wall,
esulting in destruction of the endothelium, collagen dena-
uration of the media, and fibrotic and thrombotic occlu-
ions of the vein. The endothermal ablations by laser also
rovide direct heat injury to the blood.234 Blood coagu-
ates at 70°C to 80°C, steam bubbles form at 100°C, and
arbonization of coagulum is observed at 200°C to 300°C.
urrently available laser fibers include hemoglobin-specific
aser wavelengths (810, 940, and 980 nm) and water-
pecific laser wavelengths (1319, 1320, and 1470 nm).
Laser treatment was first recommended by Puglisi235 in
989, but it was 10 years later that Boné236 reported the
rst successful clinical application of a diode laser for the
reatment of varicose veins. Boné et al237reported EVLA
rst in the English literature in 2001, and the technique was
oon adopted and perfected in the United States and
orldwide.7,238-250
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the U.S. Food and Drug Administration (FDA) in 1999,
and the first reports were published in 2000.251-253 Expe-
rience with RF rapidly accumulated,8,195,246,254-259 al-
though the first-generation device was somewhat cumber-
some to use. The current ClosureFast RF catheter (VNUS
Medical Technologies, San Jose, Calif), introduced in
2007, is more user-friendly, and treatment with it is faster
than with the first-generation device.260 This rendition
Guideline 10. Open venous surgery
Guideline
No. 10. Open venous surger
10.1 For treatment of the incompetent great saphenous v
and inversion stripping of the saphenous vein to th
10.2 To reduce hematoma formation, pain, and swelling,
compression. The recommended period of compr
10.3 For treatment of small saphenous vein incompetence
of the vein at the knee crease, about 3 to 5 cm dis
junction, with selective invagination stripping of t
vein.
10.4 To decrease recurrence of venous ulcers, we recomm
incompetent superficial veins in addition to compr
10.5 We suggest preservation of the saphenous vein using
hemodynamic treatment of varicose veins (CHIVA
patients with varicose veins, when performed by tr
10.6 We suggest preservation of the saphenous vein using
varicose vein ablation under local anesthesia (ASV
in patients with varicose veins.
10.7 We recommend ambulatory phlebectomy for treatm
performed with saphenous vein ablation, either du
a later stage. If general anesthesia is required for p
concomitant saphenous ablation.
10.8 We suggest transilluminated powered phlebectomy u
and extended tumescence as an alternative to trad
extensive varicose veins.
10.9 For treatment of recurrent varicose veins, we sugges
stump, ambulatory phlebectomy, sclerotherapy, o
depending on the etiology, source, location, and e
Table VI. Main manufacturers of endovenous ablation de
Device
Laser device name
VenaCure EVLT System Angio
Medilas D FlexiPulse Dorn
Pro-V Sciton
Vari-lase bright tip, Vari-lase platinum bright tip Vascu
Cooltouch CTEV CoolT
ELVeS PL Laser System Biolit
Radiofrequency device name
ClosureFast VNU
ClosureRFS Stylet VNU
Celon RFITT Olymdoes not need an irrigation system, and the entire pullback procedure takes 3 to 4 minutes. A second RFA system for
ipolar RF-induced thermotherapy, Celon RFITT, is now
vailable in Europe (Olympus Medical Systems, Hamburg,
ermany).261 This system generates heat at 60°C to 85°C
nd operates with a continuous pullback technique at a
ullback speed of 1 cm/s. Clinical studies to investigate the
fficacy of this device are under way.
Patient selection. To select the right patient for en-
ovenous thermal ablation, thorough preprocedural du-
GRADE of
recommendation
Level of
evidence
1. Strong A. High
quality
2. Weak B. Moderate
quality
C. Low or very
low quality
e suggest high ligation
el of the knee.
2 B
commend postoperative
in C2 patients is 1 week.
1 B
recommend high ligation
the saphenopopliteal
ompetent portion of the
1 B
blation of the
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1 A
mbulatory conservative
hnique only selectively in
venous interventionists.
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mbulatory selective
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lower oscillation speeds
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venous thermal ablation,
of varicosity.
2 C
and laser wavelengths
Manufacturer Wavelength, nm
mics, Inc, Queensbury, NY 810
edTech, Kennesaw, Ga 940
Palo Alto, Calif 1319
lutions, Inc, Minneapolis, Minn 810, 980
Inc, Roseville, Calif 1320
, East Longmeadow, Mass 1470
d Tech, San Jose, Calif
d Tech, San Jose, Calif
edical Systems, Hamburg, Germanyy
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May Supplement 201128S Gloviczki et altion of all refluxing venous segments and their ablation
during the procedure is the key to minimizing recurrence of
varicose veins. Inappropriate vein size (2 mm and 15
mm for RFA), a history of superficial thrombophlebitis
resulting in a partially obstructed saphenous vein, and the
uncommon occurrence of a tortuous GSV on duplex exam-
ination are potential contraindications. Patients with ropy
varicose veins located immediately under the skin or those
with aneurysmal dilations of the SFJ are probably better
served with conventional high ligation, division, and strip-
ping. Those with extensive deep venous occlusion should
undergo superficial ablation selectively, because superficial
veins in these patients may be important for venous outflow
from the leg.
There are no absolute contraindications to EVLA, in-
cluding vein diameter, although Lawrence et al262 have
recently suggested an association of central GSV diame-
ter 8 mm with increased risk of extension of thrombus
into the femoral vein. Other relative contraindications to
endovenous saphenous vein ablation (EVLA or RFA)
include uncorrectable coagulopathy, liver dysfunction
limiting local anesthetic use, immobility, pregnancy, and
breastfeeding.
Technique. The techniques of vein ablations using
EVLA or RFA are similar. For GSV ablation, the patient is
placed in the reverse Trendelenburg position first, and the
GSV is accessed percutaneously under ultrasonographic guid-
ance using a micropuncture needle inserted into the vein just
distal to the knee. Treatment is usually limited to the above-
the-knee segment of the vein to avoid injury to the saphenous
nerve, which is close to the saphenous vein in the calf (Fig 1).
A microguidewire is inserted in the vein, followed by place-
ment of a 4F microsheath. With the help of a floppy
guidewire, the sheath is exchanged for a 5F sheath, allow-
ing placement of the laser fiber or for an 11-cm-long 7F
sheath for placement of the RF catheter.
The laser fiber or RF probe is introduced through the
sheath into the GSV and advanced proximally to the SFJ.
The tip of the catheter is then positioned 1 cm distal to the
confluence with the superficial epigastric vein or 2 cm distal
to the SFJ. The patient is then placed in the Trendelenburg
position and the vein emptied by elevation and compres-
sion by instillation of perivenous tumescent anesthesia with
a diluted anesthetic solution (100-300 mL of the 500-mL
solution of 445 mL of 0.9N saline, 50 mL of 1% lidocaine
with 1:100,000 epinephrine, and 5 mL of 8.4% sodium
bicarbonate)232 into the saphenous subcompartment. The
vein can be further compressed by applying negative pres-
sure in the side port with a 20-mL syringe. Tumescent
anesthesia enhances contact of the vein wall with the cath-
eter or laser fiber for therapeutic effectiveness and provides
analgesia and a heat sink around the treated vein, thereby
decreasing heat-related injury to surrounding tissues,
which is reflected in a lower incidence of skin burns and
paresthesias.
The vein is then ablated in a retrograde fashion to just
above the puncture site. The laser fiber is withdrawn at a
rate of 1 to 2 mm/s for the first 10 cm and 2 to 3 mm/s for she remaining distance. For optimal treatment, 50 to 80
/cm energy is delivered when using the 810-nm diode
aser. With the RF catheter system, sequential heating of
he vein is performed at 7-cm intervals, heating the vein to
20°C in each 20-second cycle. The first segment is treated
wice. At the end of the procedure, the saphenous vein is
eimaged to confirm successful obliteration and absence of
hrombus protrusion into the femoral vein or, if the SSV
as treated, into the popliteal vein. If a patent segment is
dentified, re-treatment is advisable.
Postprocedural care. Graduated compression stock-
ngs with an ankle pressure of 30 to 40 mm Hg or an elastic
r nonelastic wrap is placed on the leg at the end of the
rocedure. Early ambulation is encouraged, and the patient
eaves for home a few hours after the procedure. Recent
vidence supports elastic compression for at least 1 week
fter superficial venous interventions.205 During this time,
he patient is asked to have compression of the leg day and
ight. Although the risk of DVT, heat-induced thrombus
xtension, or PE is rare263,264 and therefore the yield is low,
e suggest postprocedural duplex scanning within 24 to 72
ours to exclude any thrombotic complication. Evidence to
upport this recommendation is of low quality (GRADE
C).
Thrombosis prophylaxis. Data to support the rou-
ine administration of thromboprophylaxis with heparin are
ot available. Selected patients with a history of thrombo-
hlebitis, DVT, known thrombophilia, or obesity are can-
idates for thrombosis prophylaxis.159 In one case series,
ge 50 years was a predictor of heat-induced thrombus
xtension into the femoral vein.246 Lawrence et al262 re-
orted 500 patients who underwent RFA, and 13 (2.6%)
xperienced thrombus bulging into the femoral vein or
dherent to its wall, which was treated with low-molecular-
eight heparin. All of these patients had thrombus retrac-
ion to the level of the SFJ in an average of 16 days. A
ignificantly higher rate of proximal thrombus extension
as noted in those patients with a history of DVT and in
hose with a GSV diameter of 8 mm (P  .02).
For high-risk patients, several interventionists use a
ingle, preventive dose of low-molecular-weight heparin
efore or at the beginning of the procedure, although data
n the effectiveness of such prophylaxis are not available.246
erforming the operation as an outpatient procedure under
ocal or tumescent anesthesia permits early ambulation that
ecreases the risk of thromboembolic complications. In
ddition, the use of elastic compression and frequent leg
levation are also aimed at prevention of DVT or PE.
Results of EVLA. Early results from Navarro et al237
n 40 patients confirmed 100% saphenous occlusion at 4.2
onths and suggested rapid and widespread use of this
herapy. Min et al266 reported 3-year results in 499 legs
reated with laser, demonstrating a saphenous occlusion
ate of 93%. In a large single-center cohort study, Myers
nd Jolley264 treated 509 limbs with an 810-nm laser
uring a 5-year period. The rate of primary occlusion at 4
ears was 76%, and the secondary occlusion rate was 97%. A
ystematic review of EVLA for varicose veins by Mundy et
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Volume 53, Number 16S Gloviczki et al 29Sal7 found an early saphenous occlusion rate of 88% to 100%,
and a review of 13 studies showed evidence of short-term
benefits.
EVLA of the SSV has been described by several
groups.266-268 Proebstle et al260 observed a 100% occlu-
sion rate at 6 months by using a 940-nm diode laser to treat
the SSV in 41 patients. In a prospective cohort study,
Huisman et al267 treated the SSV in 169 limbs with an
810-nm diode laser. The treated length averaged 23 cm
(range, 6-53 cm). Occlusion of the SSV after 3 months was
achieved in 98%.
Knipp et al268 reported a 1-year saphenous occlusion
rate of 95.9% in 460 limbs treated with 810-nm EVLA and
observed sustained improvement using the VCSS. These
authors also found that outcomes were not affected by the
presence or absence of deep vein insufficiency.
Complications. In an international endovascular
working group registry that included 3696 procedures,
bruising after EVLA was observed in 75%, paresthesia in
3%, thrombophlebitis in 1.87%, skin burns in 0.46%, and
DVT or endovenous heat–induced thrombosis in
0.27%.263 Only one patient had a PE. In 509 patients
treated with laser by Myers and Jolley,264 thromboembolic
complications occurred in 3%. Knipp et al268 observed a
DVT rate of 2.2% in patients who underwent EVLA with
phlebectomy or perforator ligation and a thrombus exten-
sion rate into the femoral veins of 5.9%. When EVLA alone
was performed, there was 0% true DVT but a high throm-
bus extension rate (7.8%) into the femoral vein. The risk-
adjusted thrombosis prevention protocol in this study had
no effect on thrombus extension rate into the femoral vein.
Puggioni et al246 observed a 2.3% rate of thrombus exten-
sion into the femoral vein after EVLT.
Laser treatment of the SSV may result in sural nerve
paresthesia, with an incidence of 1.3% in the series of
Huisman et al.267 Superficial thrombophlebitis developed
in 6 of 169 patients (3.5%) in this study, but serious
complications did not occur.
Laser wavelength, radial fiber, and efficiency. Evi-
dence to support the efficiency of higher-wavelength vs
lower-wavelength laser fibers has been controversial. A
prospective, randomized, single-center, single-surgeon
trial evaluated lasers with 810- or 980-nm wavelengths.243
Thirty legs were treated for each group by a surgeon
blinded for the type of laser. Patients in the 980-nm group
showed less bruising than those in the 810-nm group (P
.005). Saphenous occlusion rates at 1 year, however, were
identical, and no major complications occurred in either
group. Studies by Proebstle et al240 and Pannier et al,269
however, suggest that laser light with longer wavelengths
(1320-nm Nd:YAG laser, 1470-nm diode laser) may re-
duce adverse effects without compromising abolition of
reflux.
Another recent development is the introduction of the
ELVeS Radial Fiber, a fiber with a radial emitting laser tip
(Biolitec AG, Jena, Germany), which may decrease the
amount of energy required to occlude the vein, thus de-
creasing pain and adverse effects of thermal ablations. A dCT by Doganci and Demirkilic270 compared early occlu-
ion rates of two different laser fibers. The immediate
cclusion rate was 100% for both the 980-nm laser and
are-tip fiber and the 1470-nm laser with the radial fiber.
ther clinical trials with such fibers are under way.
EVLAvs high ligation, division, and stripping. Seven
CTs250,265,271-275 compared results of laser ablation with
pen high ligation, division, and saphenous stripping. An
CT by Rasmussen et al265 found no difference in short-
erm safety and efficacy or early QOL between EVLA using
wavelength of 980 nm and HL/S, but EVLA was more
xpensive than open surgery. The recurrence rate of vari-
ose veins at 2 years was 33% after high ligation and 26%
fter EVLA (P  NS).177 The study concluded that treat-
ents were equally safe and efficient in eliminating saphe-
ous reflux, alleviating symptoms and signs of varicose
eins, and improving QOL.
Darwood et al271 performed an RCT comparing EVLA
ith surgery for treatment of primary varicosity and saphe-
ous incompetence. EVLA and surgery were comparable in
blation of reflux and in disease-specific QOL, but return to
ormal activity averaged a median of 2 days (range, 0-7
ays) after EVLA vs 7 days (range, 2-26 days) after surgical
reatment (P  .001). Return to work was 4 days (range,
-7 days) after EVLA vs 17 days (range, 7.25-33.25 days)
fter surgery (P  .005), suggesting important socioeco-
omic advantages for EVLA. These RCTs177,271 both
ound a tendency toward less bruising and pain with EVLA
han with surgery.
In a single-center RCT, de Medeiros and Luccas272
ompared EVLA using an 810-nm laser with stripping in
0 patients who had bilateral saphenous incompetence.
ach patient served as his or her own control. There was
ignificantly less edema and bruising early after the laser
rocedure, but at 2 years, no difference was noted in
sthetic results, patient satisfaction, or pain, and the authors
oncluded that midterm results of laser were comparable to
urgery.
Vuylsteke et al273 randomized 164 patients to EVLA
80 patients) or HL/S (84 patients). Patient follow-up
asted an average of 9 months after surgery. The study
ound shorter duration of postoperative disability after
VLA than after surgical treatment (8.6 vs 22.4 days; P 
05).
Kalteis et al274 reported results of a single-center RCT
omparing laser ablation (810-nm laser) with stripping of
he GSV in 100 patients, including high ligation and phle-
ectomies performed in both groups. Follow-up was 4
onths. Fewer postoperative hematomas occurred in the
aser group, but pain and sick leave time after EVLA were
onger than after surgery (20 days vs 14 days; P .05). The
tudy concluded that short-term QOL is equal after both
rocedures but that longer follow-up is needed to decide
hich is a better choice for the patients.
Pronk et al275 compared HL/S with EVLA using a
80-nm laser energy; 130 legs in 121 patients were ran-
omized. In this study, more pain was noted after EVLA at
ays 7, 10, and 14 (P  .01; P  .01; P  .01), more
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May Supplement 201130S Gloviczki et alhindrance in mobility at days 7 (P .01) and 10 (P .01),
and in self-care (P  .03) and daily activities (P  .01) at
day 7 compared with HL/S. Recurrence at 1 year was
similar in the two groups.
Christenson et al250 recently reported 2-year data of an
RCT using 980-nm laser for EVLA and compared results
with HL/S in 204 randomized patients. Additional phle-
bectomies or perforator ligations were also performed in
both groups. HL/S limbs had significantly more postoper-
ative hematomas than EVLT limbs. Two GSVs in the
EVLT group reopened and five partially reopened, but no
open GSVs occurred in HL/S limbs. The authors con-
cluded that long-term follow-up is still needed to justify
EVLA vs HL/S.
The Committee noted that four of the seven trials had
short follow-up and two trials had funding from a commer-
cial company. Overall, the quality of evidence for safety and
early efficacy was high, but evidence for long-term effec-
tiveness in these randomized studies was of low quality.
Perioperative pain was higher in the EVLA groups in two
studies, but postoperative hematomas were less frequent.
As also stated by Thakur at al,276 meaningful comparison
across randomized studies of endovenous treatments is
difficult because of considerable variations in study popu-
lations and outcome measures between trials.
Results of RFA. Nicolini277 reported 3-year results
after RFA using the first-generation device in 330 limbs and
observed a total occlusion rate of 75%, partial occlusion
(5-cm open segment) in 18%, and incomplete occlusion
(5-cm open segment) in 7%. The total occlusion rate in
multiple studies using the first-generation device ranged
from 75% to 92%, with a partial occlusion rate of between
7% and 26%.195,257,278,279
Long-term results of the Closure Study Group at 5
years after RFA using the same device were published by
Merchant et al254 in 2005. The multicenter prospective
registry comprised data from 1200 treated limbs. Occlu-
sion rates at 1, 2, and 5 years were 87.1%, 88.2%, and
87.2%, respectively. Duplex ultrasonography identified 185
limbs that had one of the following modes of anatomic
failure:
Type I failure (nonocclusion): The treated vein failed to
occlude initially and never occluded during the follow-up
(12.4%).
Type II failure (recanalization): The vein occluded after
treatment but recanalized, partly or completely, at a later
time (69.7%).
Type III failure (groin reflux): The vein trunk oc-
cluded, but reflux was detected at the groin region, often
involving an accessory vein (17.8%).
Relief from symptoms (pain, fatigue, and edema) was
noted in most patients; 70% to 80% of those with anatomic
failure remained asymptomatic compared with 85% to 94%
of those with anatomic success. Type II and type III failures
were risk factors for varicose vein recurrence. In addition,
catheter pullback speed and body mass index were the two
risk factors associated with anatomic failures. tEarly results of the new-generation RF catheter were
eported by Proebstle et al.260 A prospective, nonrandom-
zed, multicenter study treated 252 GSVs, with an occlu-
ion rate at 6 months of 99.6%. Return to normal daily
ctivities took place on the same day in more than half the
atients, with an average time of 1.0 days (standard devia-
ion, 1.9; median, 0 days; range, 0-17 days).
Complications. Serious complications from RFA, such
s DVT or thermal skin injury, were not observed in a
ulticenter, nonrandomized study of RFA using the new-
eneration RF catheter system.260 Paresthesia occurred in
.2%, thrombophlebitis in 0.8%, ecchymosis along the
ourse of the GSV in 6.3%, and skin pigmentation in 2%.
awrence et al262 reported a 2.6% rate of thrombus exten-
ion into the femoral veins after 500 RF procedures. No
emoral DVT occurred. The rate of proximal thrombus
xtension was significantly higher in patients with a history
f DVT and in those with a GSV diameter of8 mm (P
02).
RFA vs high ligation, division, and stripping. Four
CTs compared the results of RFA with those of high
igation, division, and stripping.195,278,280-282 Rautio et
l278 from Finland reported results of a single-center ran-
omized trial in 28 patients. Results at 3 years from the
ame study were reported later by Perälä et al.283 This study
ound significantly less pain with faster recovery and earlier
eturn to work after RFA than after surgery (6.5 days vs
5.6 days). Perioperative costs were higher for RFA ($794
s $360), but total societal costs were lower ($1401 vs
1926).
Lurie et al reported results of the Endovenous Radio-
requency Obliteration (Closure procedure) versus Liga-
ion and Stripping (EVOLVeS) study at 4 months195 and at
years.256 This international, multicenter, prospective
tudy randomized 85 patients to RFA or HL/S. The RFA
roup had faster recovery, less postoperative pain, fewer
dverse events, and superior QOL scores (P .05). Clinical
nd hemodynamic outcomes of RFA were comparable to
ein stripping at 2 years. The study found that at 2 years,
1.2% of limbs in the RFA group were free of superficial
eflux vs 91.7% in the surgical group (P  NS).
Stötter et al281 reported results of a single-center RCT
rom Germany comparing RFA with PIN stripping or
ryostripping, with 20 patients in each of the 3 groups. At
year, RFA showed significantly better results in QOL and
ain assessment, and the authors found significant superi-
rity regarding return to routine activity and work.
Hinchcliffe et al282 reported the results of a single-
enter trial comparing RFA with open surgery in 16 pa-
ients with bilateral recurrent GSV varicose veins after
revious bilateral high ligation without stripping. One leg
hosen at random was treated with RFA, the other with
tripping, and both sides had phlebectomies. The time
equired to perform RFA was significantly shorter (25 vs 40
inutes), and pain and bruise scores were significantly
ower for RFA than for stripping. Follow-up was 1 year.
he authors concluded that RFA is the technique of choiceo treat the incompetent GSV.
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Volume 53, Number 16S Gloviczki et al 31SThe Committee noted that these studies had short-
term to medium-term follow-up, 1 year in two studies, 2
years in one study, and 3 years in the fourth study. RFA
treatment resulted in faster return to work and normal
activities, higher patient satisfaction, less pain, and better
short-term QOL scores, with high-quality evidence con-
firming early efficacy and safety. The studies, however, did
not report bias protection measures; therefore, the evi-
dence of midterm efficacy is of low quality and no evidence
is available on long-term efficacy.
Radiofrequency ablation vs endovenous laser abla-
tion. Four RCTs compared RFA with EVLA.255,280,284-286
Morrison255 reported a single-center randomized trial per-
formed in 50 patients with bilateral GSV reflux. One limb
was treated with RFA and the other with EVLA. The
saphenous occlusion rate was 80% with RFA and 66% with
EVLA (P  NS), and there was no difference in early
complication rates.
In the prospective, industry-sponsored, multicenter
Radiofrequency Endovenous ClosureFAST versus Laser
Ablation for the Treatment of Great Saphenous Reflux:
A Multicenter, Single-blinded, Randomized Study
(RECOVERY) trial, Almeida et al286 randomized 87
limbs to treatment with RF catheter or 980-nm EVLA.
There were no major complications. All scores referable
to pain, ecchymosis, and tenderness were statistically
lower in the catheter group at 48 hours, 1 week, and 2
weeks. Minor complications were more prevalent in the
EVLA group (P  .02). VCSS and QOL measures were
lower in the catheter group at all evaluations.286
In a similar trial, Shepherd et al285 randomized 131
patients to treatment with a new-generation RF catheter or
980-nm EVLA. Perioperative pain was less after RFA than
after laser, but clinical and QOL improvements were similar
in both groups at 6 weeks.
A recent RCT by Gale et al284 compared results of
810-nm wavelength laser with RFA. All veins were closed at
1 week after the procedure. The recanalization rate at 1 year
was significantly higher in the RF group (ClosureFAST
system) than after laser (11 of 48 vs 2 of 46, P .002). The
Guideline 11. Endovenous thermal ablation
Guideline
No. 11. Endovenous thermal abla
11.1 Endovenous thermal ablations (laser and radiofrequ
effective, and we recommend them for treatmen
incompetence.
11.2 Because of reduced convalescence and less pain and
endovenous thermal ablation of the incompetent
surgery.mean VCSS score change from baseline to 1 week postpro- medure was higher for RFA than EVLA (P  .002), but
here was no difference between groups at 1 month (P 
07) and 1 year (P .9). The authors concluded that both
ethods of endovenous ablation effectively reduce symp-
oms of superficial venous insufficiency. EVLA was associ-
ted with greater bruising and discomfort in the perioper-
tive period but may provide a more secure long-term
losure than RFA.
The Committee noted that the data support less bruis-
ng and less pain with the new RF catheter system than with
he 980-nm EVLA. However, further trials with higher-
avelength EVLA, as well as with long-term follow-up, are
eeded before any conclusion on the use of any EVLA vs
FA can be made.
Hemodynamic improvement after saphenous abla-
ions. In a comparative nonrandomized study, Marston et
l287 observed both hemodynamic and clinical improve-
ent in patients treated by either RFA or laser. These
uthors reported significant improvements in venous filling
ime and in VCSS, with no differences between the groups.
clerotherapy
Injection of a chemical into the vein to achieve endo-
uminal fibrosis and obstruction of the vein has been used
or almost a century.288 Sigg et al,289,290 Fegan et al,291,292
ournay,293 and Wallois294 are considered the pioneers of
iquid sclerotherapy, whereas Hobbs295 was the first to
rovide scientific evidence on the clinical outcome after
clerotherapy compared with surgery. Sclerotherapy in
ome European countries, especially in France, has been a
ery popular treatment for varicose veins.296-299 Although
iquid sclerotherapy has been used primarily for obliteration
f spider veins or telangiectasia (veins3 mm in diameter),
nterest in the use of sclerotherapy greatly increased when
abrera et al300 reported in 1995 that foam prepared by
ixing a “physiologic gas” with the detergent polidocanol
as effective for obstruction of larger veins. Ultrasono-
raphically guided foam sclerotherapy has rapidly spread
or treatment of primary and recurrent varicose veins, in-
luding the GSV and SSV, perforating veins, and venous
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May Supplement 201132S Gloviczki et alSclerosing agents. The mechanisms of action of scle-
rosing solutions are the destruction of venous endothelial
cells, exposure of subendothelial collagen fibers, and ulti-
mately, the formation of a fibrotic obstruction. The higher
the concentration of the solution and the smaller the vein,
the greater the endothelial damage. Delivery of the solution
as a foam prolongs the time of contact and amplifies the
effect of the chemical. In the United States, current FDA-
approved agents for sclerotherapy include sodium tetrade-
cyl sulfate (STS), polidocanol, sodium morrhuate, and
glycerin, which is usually used with epinephrine. Hyper-
tonic saline, although not approved for sclerotherapy in the
United States, has also been used for many years (Table
VII).
Osmotic agents. Hypertonic saline is a weak hyperos-
molar sclerosing agent that causes dehydration of endothe-
lial cells through osmosis, which leads to endothelial cell
death. The usual concentration is used in 23.4% sodium
chloride. One formulation is manufactured as Sclerodex
(Omega Laboratories Ltd, Montreal, Quebec, Canada).
Burning pain is frequent during injection. Extravasation
may cause skin ulcers and tissue necrosis, and osmotic
agents are used for occlusion of small veins only.
Detergents. Detergents destroy the endothelium by
Table VII. Sclerosing agent comparison
Agent Manufacturer Category FDA app
Hypertonic saline Multiple Osmotic Off-label
usage
Sclerodex (hypertonic
saline and dextrose)
Omega
Laboratories,
Montreal,
Quebec
Osmotic Not appr
Chromex (72%
chromated
glycerin)
Omega
Laboratories,
Montreal,
Quebec
Alcohol
agent
Not appr
Nonchromated
glycerin
Compounded at
pharmacy
Alcohol
agent
Off-label
usage
Scleromate
(morrhuate
sodium)
Glenwood, LLC,
Englewood,
New Jersey
Detergent Approved
Sotradecol (sodium
tetradecyl sulfate)
Bioniche Pharma
USA, Lake
Forest, Ill
(distributed by
AngioDynamics
Inc,
Queensboro,
NY)
Detergent Approved
FDA, Food and Drug Administration.denaturation of the cell surface proteins. STS (as Sotrade- ool, Bioniche Pharma USA, Lake Forest, Ill; Fibro-Vein,
TD Pharmaceutical Products Ltd, Hereford, UK; Trom-
oject, Omega Laboratories) is a long-chain fatty alcohol.
critical micellar concentration is needed to cause endo-
helial cell injury, and repeated treatments are frequently
esirable. The solution is safe and painless when injected.
hen the solution is injected in higher concentration,
xtravasation may result in tissue necrosis. Hyperpigmen-
ation, matting, and allergic reactions have been described.
oaming of this agent is easy and will result in longer
xposure of the agent to the vein wall using a smaller
mount of the solution.
Polidocanol (Asclera injection, Bioform Medical Inc,
an Mateo, Calif), another detergent, was approved for use
n the United States in 2010. This is the most commonly
sed sclerotherapy agent in the world; it is safe and painless
hen injected, with a low risk of tissue necrosis when used
n a low concentration. It may cause hyperpigmentation,
ut has a very low rate of allergic or anaphylactic reaction.
Morrhuate sodium (Scleromate, Glenwood, LLC,
nglewood, NJ) is a detergent that is used less frequently
ecause of the relatively higher incidence of skin necrosis
bserved with extravasation and because of the higher risk
Strength Advantages Disadvantages
  Low risk of allergic
reaction; wide
availability; rapid
response
Off label; painful to
inject;
hyperpigmentation;
necrosis; rapid
dilution; not
recommended for
facial veins
  Low risk of allergic
reaction; low risk of
necrosis; high
viscosity
Not FDA-approved;
stings when
injected;
hyperpigmentation
 Low incidence of
hyperpigmentation,
necrosis, and
allergic reaction
Not FDA-approved;
weak sclerosing
agent; highly
viscous and painful
to inject; may
cause hematuria at
high doses
 Low incidence of
hyperpigmentation,
necrosis, and
allergic reaction
Weak sclerosing
agent; typically
only used for
telangiectasia
   FDA-approved High incidence of
skin necrosis and
anaphylaxis
     FDA-approved; low
risk of allergic
reaction; potent
sclerosant
Potential necrosis
with extravasation;
telangiectasia
mattingroval
oved
ovedf anaphylactic reactions.
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Volume 53, Number 16S Gloviczki et al 33SAlcohol agents. Alcohol agents are weak sclerosants
that cause irreversible endothelial damage by contact. Glyc-
erin is a corrosive agent that destroys the cell surface
proteins by affecting chemical bonds. Chromated glycerin
is used most frequently as a solution of glycerin, sterile
water, and benzyl alcohol (Chromex, Omega Laboratory).
It is not approved in the United States. It is usually mixed
with 1% lidocaine and epinephrine. Chromated glycerin is
safe and rarely leads to tissue necrosis, hyperpigmentation,
or allergy. Suitable for treatment of small veins or telangi-
ectasia, it may cause hematuria when used in a higher
concentration.
Liquid sclerotherapy. The sclerosing chemicals need
to be diluted before use, and the concentration of the
solution should be the lowest when used for treatment of
very small diameter veins, such as telangiectasia. Recom-
mended concentrations of STS and polidocanol are listed in
Table VIII.
Liquid sclerotherapy is performed using small tubercu-
lin syringes and a 30- or 32-gauge needle. Treatment is
usually started with larger varicose veins and ends with
reticular veins and telangiectasia. The proximal part of the
limb is treated first and the distal part second. Using loupes
for magnification and transillumination (Veinlite, Trans-
Lite, Sugar Land, Tex; VeinViewer, Luminetx, Memphis,
Tenn) helps intraluminal injection and avoids extravasation
of the drug. The injection maximum of 1.0 mL of the
chemical to one site is recommended, with not more than
10 to 20 injections performed per session. Severe pain
during injection may signal extravasation, and further in-
jection should be avoided.29 Gauze pads are placed on the
injection sites, and the patient is instructed to wear 30 to 40
mm Hg graduated compression stockings for 1 to 3 days
after treatment of telangiectasia and reticular veins and at
least 1 week after treatment of varicose and perforating
veins.
Foam sclerotherapy. Foam sclerotherapy of the sa-
phenous vein is the least invasive of the endovenous abla-
tion techniques. The European Consensus Meetings on
Foam Sclerotherapy308,309 reported that foam was an ef-
fective, safe, and minimally invasive endovenous treatment
for varicose veins with a low rate of complications.
The most popular technique used today was developed
by Tessari et al312 using a three-way stopcock connected
with two syringes. Experts recommend a ratio of 1 part
solution of STS or polidocanol to 4 or 5 parts of air.313
Table VIII. Indications and concentrations of sclerosing
agents
Indications STS Polidocanol
Varicose veins 8 mm 0.5%-3.0% 1%-3%a
Reticular veins 2-4 mm 0.25%-0.5% 0.6%-1.0%
Telangiectasias 0.1-2.0 mm 0.125%-0.25% 0.25%-0.6%
STS, Sodium tetradecyl sulfate.
aNot approved for varicose veins in the United States.Mixing the drug with air using the two syringes and push- lng the mixture from one syringe into the other 20 times
esults in an approximate bubble size of 100 m.
Coleridge-Smith306 advises to cannulate the veins in
upine patients and then elevate the limb 30° to inject the
oam. Ultrasonography is used to monitor the movement
f foam in the veins. The saphenous trunk is injected first,
ollowed by varicose and perforating veins if indicated. A
aximum of 20 mL of foam is injected during one session.
ergan313 recommends elevation of the limb for 10 to 15
inutes after injection to minimize the volume of foam
hat gets into the systemic circulation. The procedure is
ompleted by placing a short stretch bandage or 30 to 40
m Hg graduated compression stockings (or both) on
he limb. Although most authors recommend 1 to 2
eeks of compression,313,314 a recent RCT found no
dvantage to compression bandaging for 24 hours
hen thromboembolus-deterrent stockings were worn
or the remainder of 14 days.315
Complications. Severe complications after sclerother-
py, such as death, anaphylactic reaction, pulmonary em-
oli, stroke, and large areas of skin necrosis, are very rare
0.01%).316 Severe but rare complications also include
hrombophlebitis, nerve damage (saphenous, sural), DVT,
r inadvertent arterial injection of the solution.317,318
ransient neurologic adverse effects such as visual distur-
ance, migraine-like headache, or confusional state may
ccur and are more frequent in patients with a patent
oramen ovale.319
Most complications are minor, and include matting,
igmentation, pain, allergy, and skin urticaria. The higher
he concentration of the agent, the higher the likelihood of
yperpigmentation, a minor complication that can be ob-
erved in up to 30% of the cases.320 Between 70% and 95%
f the pigmentations, however, resolve by 1 year after
herapy.317
The incidence of major neurologic events after foam
njection is rare; instances of stroke were reported by Bush
t al321 and others.319,322,323 Immediate treatment with
00% oxygen and possibly hyperbaric oxygen therapy
hould be considered. Factors implicated in the risk of stroke
fter foam sclerotherapy include the use of air instead of
arbon dioxide to prepare the foam, large bubble size, a patent
oramen ovale, failure to elevate the limb after treatment,
rolonged immobility after therapy, and an excessive amount
f foam used during one session.319,322-324 Standardization
f the bubble size using commercially prepared micro-
oam and the replacement of air with carbon dioxide in
he solution may decrease the risk of neurologic
omplications.325
A recent study Regan et al326 proposed that the com-
osition and properties of the foam, including bubble size
nd gaseous components, may indeed contribute to the
otential for microcirculatory obstruction and cerebral
schemia. The authors tested an ultralow nitrogen polido-
anol endovenous microfoam with controlled bubble size
nd density and found that patients treated with foamed
iquid sclerosants are commonly exposed to cerebrovascu-
ar gas bubbles. In a series of 60 high-risk patients with
c
b
p
7
s
i
m
c
s
3
3
c
d
s
G
(
d
.
(
i
g
8
f
S
f
4
o
l
e
r
w
v
c
D
g
v
a
m
e
m
e
i
w
t
t
s
t
c
i
JOURNAL OF VASCULAR SURGERY
May Supplement 201134S Gloviczki et almiddle cerebral artery bubble emboli during or after treat-
ment, however, there was no evidence of cerebral or cardiac
microinfarction.
Although rare, allergic reactions and anaphylaxis af-
ter injection of a sclerosing solution can occur, and it is
essential to have an emergency protocol, resuscitation
equipment, oxygen, and drugs (diphenhydramine, epi-
nephrine, cimetidine, steroids) available to prevent a
major catastrophe.
Guex et al296 reported early and midterm complica-
tions in a prospective multicenter registry that included
12,173 sclerotherapy sessions, consisting of 5434 with
liquid, 6395 with foam, and 344 using both. Ultrasono-
graphic guidance was used in 4088 sessions (33.9%), and
49 incidents or accidents (0.4%) occurred, of which 12
were with liquid and 37 with foam. There were 20 cases of
visual disturbances, in 19 cases, foam or air block was used;
all resolved shortly, without any after effects. A femoral vein
thrombosis was the only severe adverse event in this study,
which also demonstrated that sclerotherapy is a safe
technique.
A systematic review of foam sclerotherapy also found a
low rate of major complications.10 In 9000 patients
studied, the median rates of serious adverse events, includ-
ing PE and DVT, were rare,1%. The median rate of visual
disturbance was 1.4%, headache occurred in 4.2%, throm-
bophlebitis in 4.7%, matting, skin staining, or pigmentation
in 17.8%, and pain at the site of injection in 25.6%.
Morrison et al327 evaluated the safety of carbon dioxide
in patients undergoing 1% polidocanol foam sclerotherapy
and compared them with a historical control of patients
who had air mixed with the sclerosing agent. The carbon
dioxide–based foam group had 128 patients (115 women
and 13 men). Visual disturbances were experienced by 3.1%
(4 of 128) of the carbon dioxide group and in 8.2% (4 of
49) of the air group (P  .15). The incidence of chest
tightness (3.1% vs 18%), dry cough (1.6% vs 16%), and
dizziness (3.1% vs 12%) was significantly lower in the
carbon dioxide group compared with the air group (P 
.02). Nausea occurred in 2% of the carbon dioxide foam
group and in 4% of the air foam group (P  .53). Overall,
the proportion of patients describing adverse effects de-
creased from 39% (19 to 49) to 11% (14 to 128) as carbon
dioxide replaced air for foam preparation (P  .001). The
authors concluded that adverse effects decreased signifi-
cantly if carbon dioxide rather than air was used to make the
sclerosing foam for chemical ablation of superficial veins of
the lower extremity.
Results. Short-term and midterm results of liquid
sclerotherapy have been good for both reticular and vari-
cose veins, but durable success depends largely on the
presence or absence of axial reflux. Those with untreated
incompetent saphenous veins have the highest rate of re-
currence.295,328 Kern et al329 reported results of liquid
sclerotherapy of telangiectasia and reticular veins in 96
patients. Those who wore elastic stockings for 3 weeks after
treatment had an early success rate of 76%. Goldman330published results of a prospective trial comparing the effi- facy of two liquid sclerosants, polidocanol and STS, and
oth were used to treat varicose and telangiectatic veins. All
atients had an average of 70% improvement, and 70% to
2% were satisfied in all vein categories treated with either
olution.
Liquid sclerotherapy does poorly for treatment of the
ncompetent GSV, but results of foam sclerotherapy are
uch more encouraging. Rabe et al331 performed a multi-
enter RCT to evaluate the efficacy and safety of GSV
clerotherapy using standardized polidocanol foam. The
% foam was more efficient than and equally as safe as the
% liquid for the treatment of the incompetent GSV.
In a prospective comparative study, Yamaki et al332
ompared results of duplex-guided foam sclerotherapy and
uplex-guided liquid sclerotherapy in 77 patients. Duplex
canning at 1 year demonstrated complete occlusion in the
SV for duplex-guided foam sclerotherapy in 25 limbs
67.6%), which was a significantly higher rate than that for
uplex-guided liquid sclerotherapy in 7 limbs (17.5%; P 
0001). Recurrent varicose veins were found in 3 patients
8.1%) in the duplex-guided foam sclerotherapy group and
n 10 (25%) in the duplex-guided liquid sclerotherapy
roup at 1 year (P  .048). Cabrera et al333 reported an
0% occlusion rate at 4 to 6 years when they used micro-
oam to treat incompetent GSV in 415 limbs.
In 808 patients with 1411 affected limbs, Coleridge
mith306 used 1% polidocanol, 1% STS, and 3% STS in the
orm of foam to treat incompetent saphenous trunks, and
59 limbs were available for duplex imaging at a follow-up
f 6 months. The GSV remained obliterated in 88% of
imbs and the SSV in 82%.
A Cochrane review on sclerotherapy published by Tisi
t al40 in 2006 concluded that evidence supports the cur-
ent place of sclerotherapy in modern clinical practice,
hich is usually limited to treatment of recurrent varicose
eins after surgery and thread veins.
The efficacy of foam sclerotherapy on QOL was re-
ently demonstrated in a single-center cohort study by
arvall et al.334 These author found that ultrasound-
uided foam sclerotherapy for great and small saphenous
aricose veins leads to significant improvements in generic
nd disease-specific health related QOL for at least 12
onths after treatment.
Surgery vs sclerotherapy. A Cochrane review in 2004
xamined results of surgery vs sclerotherapy for the treat-
ent of varicose veins. Rigby et al335 reviewed 2306 refer-
nces that included 61 comparative studies and 9 random-
zed trials. The study observed a trend that sclerotherapy
as better at 1 year and surgery had a better outcome at 3
o 5 years. The meta-analysis concluded, however, that
here was insufficient evidence to preferentially recommend
clerotherapy for treatment of varicose veins over surgical
reatment.
Wright et al325 reported the effect of polidocanol mi-
rofoam and compared its use with surgery or sclerotherapy
n the management of varicose veins. This European RCT
ound that 1% microfoam was inferior to surgery but supe-
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pain and earlier returns to work than surgery.
In a systematic review on foam sclerotherapy, Jia et al10
analyzed data of 69 studies, including 10 RCTs. All patients
underwent foam sclerotherapy for varicose veins, most
frequently with use of polidocanol to ablate the GSV or
SSV. The median rate of complete occlusion of treated
veins was 87%. Meta-analysis for complete occlusion sug-
gested that foam sclerotherapy was less effective than sur-
gery (RR, 0.86; 95% CI, 0.67-1.10) but more effective
than liquid sclerotherapy (RR, 1.39; 95% CI, 0.91-2.11),
although there was substantial heterogeneity between stud-
ies. The authors concluded that there is currently insuffi-
cient evidence to allow a meaningful comparison of the
effectiveness of this treatment with that of other minimally
invasive therapies or surgery.
Surgery vs endothermal ablations vs foam sclero-
therapy. A systematic review and meta-analysis of RFA,
EVLA, and foam sclerotherapy for primary varicose veins
was reported by Luebke and Brunkwall9 in 2008. Results
were compared with those achieved with conventional li-
gation and vein stripping. This study included 29 EVLA
studies, 32 RFA studies, and 22 foam sclerotherapy trials.
RFA was inferior to EVLA and foam sclerotherapy in
saphenous occlusion rate, phlebitis, DVT, and paresthesias.
EVLA had the highest occlusion rate and least recurrence
compared with RFA and foam. Foam sclerotherapy of
varicose veins was associated with a higher recurrence rate
in patients with saphenofemoral incompetence compared
with the rates after EVLA or RFA. This study concluded
that EVLA, RFA, and foam sclerotherapy seem to be safe
and effective, with good short-term and midterm results,
but large, high-quality, prospective RCTs comparing en-
dovenous techniques and endovenous techniques with sur-
gery are needed before considering endovenous techniques
as the standard treatment of varicose veins.
In a subsequent meta-analysis of EVLA results, van den
Bos et al248 compared RFA, foam sclerotherapy, and
HL/S. They analyzed results of 64 clinical trials that in-
cluded treatment of 12,320 limbs with an average fol-
low-up of 32.2 months. The estimated pooled success rate
at 3 years was highest after EVLA (94%), followed by RFA
Guideline 12. Sclerotherapy of varicose veins
Guideline
No. 12. Sclerotherapy of varicose
12.1 We recommend liquid or foam sclerotherapy for te
and varicose veins.
12.2 For treatment of the incompetent saphenous vein,
endovenous thermal ablation over chemical abla(84%), HL/S (78%), and foam sclerotherapy (77%). EVLA uas significantly superior to other treatment modalities in
bolition of the saphenous reflux. Foam therapy and RFA
ere equally effective as surgery. The meta-analysis con-
luded that endovenous thermal ablations or foam sclero-
herapy is at least as effective as surgery for treatment of
aricose veins.
Another large meta-analysis of the SVS and AVF on
aricose vein treatment is reported by Murad et al12 in this
ssue the Journal of Vascular Surgery. The authors exam-
ned data from 8207 patients reported in 38 comparative
tudies that included 29 RCTs. Each study included two or
ore treatments, such as surgery, laser ablation, RFA, and
iquid or foam sclerotherapy. The meta-analysis found that
urgery was associated only with a nonsignificant reduction
n varicose vein recurrence, compared with sclerotherapy,
aser therapy, or RFA. Studies of laser therapy, RFA, and
oam sclerotherapy, however, demonstrated short-term ef-
ectiveness and safety. The authors concluded that low-
uality evidence supports long-term safety and efficacy of
urgery for the treatment of varicose veins and that short-
erm studies support the efficacy of less invasive treatments,
hich are associated with less early disability and pain.
Results of these meta-analyses and data of several RCTs
nd single-treatment cohort studies as well as a recent re-
iew336 and an editorial337 now question the continuing role
f open surgery with HL/S as the gold standard for treatment
f varicose veins. On the basis of the available data, the Joint
ommittee of the SVS/AVF agreed that because of the
inimally invasive nature and similar or better early-term and
quivalent midterm results, endovenous thermal ablations
hould be recommended over open surgery as the first line of
reatment of varicose veins associated with axial reflux. The
ommittee also recognized that results of foam therapy have
mproved but that they are not yet equivalent to those ob-
ained after endovascular or open venous surgery. The Com-
ittee recommended that there was an urgent need for well-
erformed, large RCTs comparing adverse effects and long-
erm saphenous occlusion rates of surgery, endovenous
hermal ablations, and foam sclerotherapy. These studies
hould include detailed analyses of safety and costs and should
lso evaluate the QOL of patients who undergo treatment
GRADE of
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Perforating veins
An association between incompetent perforating veins
and venous ulcers was established more than a century ago
by Gay,338 and surgical perforator interruption was recom-
mended to treat venous ulcers by Homans,339 Linton,340
Cockett et al,341,342 and Dodd.343 Hauer344 introduced
SEPS in 1985, O’Donnell345 was the first to use laparo-
scopic instrumentation, while the Mayo Clinic team346 and
Conrad347 improved the technique and added carbon di-
oxide insufflation to the procedure. Between 1992 and
2008, SEPS became the technique of choice for perforator
ablation, primarily because of the reduced rate of wound
complications.62,348-350
However, the emergence of ultrasonographically guided
thermal ablations and sclerotherapy in recent years has trans-
formed the techniques of perforator ablation.351-356 Advan-
tages of percutaneous ablation of perforators (PAPS) in-
clude the low risk of a minimally invasive procedure that is
easily repeatable and can be performed under local anesthe-
sia in an office setting.357
Techniques of perforator ablation
Subfascial endoscopic perforator vein surgery. SEPS is
performed under general or epidural anesthesia. The single
or the double endoscopic port techniques can be used for
dissection and division of medial calf perforators.62,348-350
Most authors use balloon dissection and carbon dioxide
insufflation with a pressure of 30 mm Hg and a pneumatic
thigh tourniquet inflated to 300 mm Hg to avoid any
bleeding in the surgical field.358 Division of the fascia of the
deep posterior compartment with a paratibial fasciotomy is
required to identify all important medial perforating veins.
Occlusion of the perforators can be done with endoscopic
clips, although most surgeons use an ultrasonic harmonic
scalpel for division and transection of the perforators. The
wounds are closed, the tourniquet is deflated, and the
extremity is wrapped with an elastic bandage. The opera-
tion is an outpatient procedure, and patients are encour-
aged to ambulate 3 hours after the operation.
Percutaneous ablation of perforators. PAPS is per-
formed under ultrasound guidance, with direct needle
puncture of the perforating vein. Local anesthesia is used,
with the patient in the reversed Trendelenburg position to
allow for full venous distention. The tip of the needle
should be at or just below the fascia in the vein to minimize
deep vessel and nerve injury.
Radiofrequency ablation. The ClosureRFS Stylet is a
new intravascular ablation device (VNUS Medical Tech-
nologies, San Jose, Calif) available for RFA of the perforat-
ing vein. Intraluminal placement of the RF stylet is con-
firmed by ultrasonography and also by measuring
impedance: values between 150 and 350 ohms indicate the
intravascular location of the tip of the probe. Local anes-
thesia is used to infiltrate the tissues around the stylet before
treatment, and the patient is then placed in the Trendelen-
burg position. Treatment is performed with a target tem- aerature of 85°C. All four quadrants of the vein wall are
reated for 1 minute each. The catheter is then withdrawn 1
r 2 mm, and a second treatment is performed. The treat-
ent is finished with applying compression to the region of
he treated perforating vein.
Endovenous laser ablation. For laser treatment of per-
orating veins, a 16-gauge angiocatheter (for a 600-m
aser fiber) or a 21-gauge micropuncture needle (for a
00-m laser fiber) can be used.357 Intraluminal placement
f the access catheter is confirmed by ultrasonography and
y aspiration of blood at or just below the fascial level. Once
he fiber is positioned in the vein at or just below the level
f the fascia, local anesthesia is infiltrated, and various
ethods of energy application are used. Elias357 recom-
ends a pulsed technique with the generator set for 15
atts and a 4-second pulse interval. Each segment of vein is
reated twice, thus giving 120 J to each segment. Three
egments are usually treated. Proebstle and Herdemann359
lso treat the perforating veins at three locations, each
egment receiving between 60 and 100 J. The rest of the
rocedure is similar to RFA.
Sclerotherapy. For chemical ablation of perforating
eins, a 25-, 27-, or 30-gauge needle can be used for
annulation. If the anatomy allows, a wire may be placed
nto the deep system for better control of the access.
ltrasonographically guided sclerotherapy has been re-
orted using morrhuate sodium,351 although most experts
ecommend STS or polidocanol foam. Care should be
aken to avoid injection of the agent into the accompanying
rtery. During injection of 0.5 to 1 mL of the sclerosant,
he patient’s leg is elevated to avoid flow into the deep
ystem. After treatment, compression is applied over the
reated perforators.357
Complications. SEPS is safe and complications are
are. Death or PE has not been reported, and the North
merican SEPS registry had no patient with DVT30 days
f the procedure. Wound infection and saphenous neural-
ia occurred in 6% each. In an RCT, Pierik et al360 observed
significantly higher rate of wound complications after
pen perforator ligation, using a modified Linton proce-
ure, than after endoscopic perforator ligation (53% vs 0%;
 .001).
Complications after PAPS are rare, and in a review of
ublished series, O’Donnell356 found evidence of tibial
ein DVT in three series and foot drop and skin burn in one
ach. Masuda et al351 treated 80 limbs with sclerotherapy of
he perforating veins. There were no cases of DVT involv-
ng the deep vein adjacent to the perforator injected. One
atient had skin complications with skin necrosis.
Results of perforator ablation
Subfascial endoscopic perforator vein surgery. Most
eries of SEPS were performed in patients with advanced
isease (class C3-C6, mostly C5 and C6), and perforator
nterruption was performed with ablation of the incompe-
ent superficial system. Therefore, benefit directly attribut-
ble to perforator interruption is not well known.
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Kianifard et al361 analyzed the benefits of adding SEPS to
saphenofemoral ligation and stripping of the GSV in patients
with class C2 disease. The study allocated 38 to the SEPS
group and 34 to the no-SEPS group. The two groups were
similar with respect to pain, mobility, varicose vein recurrence,
and QOL scores during the 1-year follow-up. A significantly
higher proportion of patients in the no-SEPS group had
incompetent perforating veins on duplex imaging at 1 year
(25 of 32 vs 12 of 38; P .001). This RCT concluded that at
1 year in class C2 patients, no additional clinical benefit could
be observed when SEPS was added to HL/S.
This finding was supported by a prospective study by
van Neer et al362 in 62 limbs with class C2 disease, who had
varicose veins distal to the knee and underwent HL/S of
the GSV to the level of the knee. Clinical and ultrasono-
graphic residual varicose veins at 6 months were not signif-
icantly related to the presence of preoperative incompetent
perforating veins.
Chronic venous insufficiency (CEAP class C3-C6). The
North American SEPS registry reported the results of SEPS
performed in 17 U.S. centers on 155 limbs, 85% with class
C5 and C6 disease. Ulcer healing at 1 year was 88%, with the
median time to ulcer healing of 54 days.62,350 Ulcer recur-
rence was 16% at 1 year and 28% at 2 years. This registry
contained data on 27 patients with class C6 disease who
underwent SEPS alone. The ulcer recurrence rate (35%) in
the SEPS-only group at 2 years was not significantly higher
than recurrence in patients who underwent SEPS and su-
perficial ablation alone (25%).
Nelzen363 prospectively collected data from 149 SEPS
procedures in 138 patients, of whom 89% underwent sa-
phenous surgery as well. During a median follow-up of 32
months, 32 of 36 ulcers healed, more than half (19 of 36)
1 month. Three ulcers recurred, one of which subse-
quently healed during follow-up. In a subsequent series
from the same group, 97 limbs with class C5 and C6 disease
were treated with SEPS. Superficial ablation was also per-
formed in 87%. All patients were monitored for at least 5
years. Ulcers healed in 87%, and the 3- and 5-year recur-
rence rates were 8% and 18%. Long-term data in 51 limbs
with class C5 and C6 disease were published by Iafrati et
al,364 who performed SEPS alone in 23 limbs and SEPS
with stripping in 28. The ulcers healed rapidly, and the
5-year ulcer recurrence rate was low (13%).
Post-thrombotic patients do worse than those with
primary incompetence. In the Mayo Clinic series, 5-year
ulcer recurrence was 56% in post-thrombotic patients vs
15% in patients with primary valvular incompetence (P 
.05).365,366 Post-thrombotic patients with significant deep
venous disease still gained some benefit, as measured by
improved VCSS as well as an apparent ease in treating the
smaller and more superficial ulcers compared with their
preoperative state.
A single-center cohort study by Bianchi et al367 ob-
served ulcer healing in 91% (53 of 58) of limbs with C6
disease at a mean of 2.9 months (range, 13 days-17
months) after SEPS and saphenous stripping. Ulcer recur- cence at 30 months was 6%. Ulcer recurrence at 4 years
as as high as 31% in the ESCHAR study when compres-
ion treatment was combined with surgical ablation of
he superficial reflux, but no perforator interruption was
erformed.157
In a large, retrospective, multicenter cohort study,
awes et al368 monitored 832 patients with CEAP clinical
lass C4 to C6 for 9 years after SEPS. Only 55% of the
atients underwent HL/S in addition to SEPS. In this
tudy, 92% of ulcers healed with only 4% recurrences. There
as a 3% nonfatal complication rate, and significant im-
rovement was documented in venous hemodynamics in a
ubset of patients.
In a systematic review, Tenbrook et al38 reported re-
ults of the SEPS procedure performed with or without
uperficial ablation on 1140 limbs in 1 RCT and 19 case
eries. Ulcers in 88% of limbs healed and recurred in 13%, at
mean time of 21 months. Risk factors for nonhealing and
ecurrence included postoperative incompetent perforating
eins, pathophysiologic obstruction, previous DVT, and
lcer diameter2 cm. The authors concluded that surgical
reatment, including SEPS, with or without saphenous
blation, is recommended for patients with venous ulcers,
ut RCTs are needed to discern the contributions of com-
ression therapy, superficial venous surgery, and SEPS in
atients with advanced CVI.
The Dutch SEPS RCT59 compared results of surgical
reatment in 103 patients (SEPS, with or without superfi-
ial reflux ablation) with medical treatment in 97 patients
ith venous ulcers. The rate of ulcer healing at 29 months
n the surgical group was 83%, with recurrence of 22%. In
he conservative treatment group, ulcers healed in 73% and
ecurred in 23% (PNS). The study concluded that SEPS,
ith or without superficial ablation, failed to improve heal-
ng or recurrence over best medical treatment. Ulcer size
nd duration were independent factors adversely affecting
lcer healing and recurrence. In a subgroup analysis, medial
lcers, recurrent ulcers, or SEPS done in centers of excel-
ence did show significant benefit. In this study, 86% of the
atients had medial or recurrent ulcers. On the basis of
hese data and results of a previous RCT by Stacey et al,369
he evidence summary of O’Donnell19 concluded that fur-
her properly conducted RCTs are needed to provide high-
uality evidence of efficacy of perforator interruptions in
atients with leg ulcers. Previous AVF recommendations
greed with this statement.370
A recent meta-analysis of SEPS by Luebke and Brunk-
all32 reviewed data of studies published between 1985
nd 2008 and concluded that SEPS, used as part of a
reatment regimen for severe CVI, benefits most patients in
he short-term regarding ulcer healing and the prevention
f ulcer recurrence. SEPS is safe and has less early postop-
rative complications compared with the classic Linton
rocedure. Luebke and Brunkwall also concluded that fur-
her prospective RCTs are needed to define the long-term
enefits of SEPS.
Hemodynamic improvement after SEPS with superfi-
ial ablation was confirmed by Padberg et al,127 who per-
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used air plethysmography, foot volumetry, and duplex
scanning to assess results. At a median follow-up of 66
months, expulsion fraction and half-refilling time had both
improved significantly in patients, with no ulcer recurrence.
Rhodes et al,95 from Mayo Clinic, used strain-gauge pleth-
ysmography to quantitate calf muscle pump function and
venous incompetence before and after SEPS. Significant
improvement was noted in both calf muscle pump function
and venous incompetence in 31 limbs studied 6 months
after SEPS. Saphenous stripping was done in addition to
SEPS in 24 of the 31 limbs. Although the seven limbs
undergoing SEPS alone had significant clinical benefits, the
hemodynamic improvements were not statistically signifi-
cant. It is important to note also that Akesson et al371 failed
to show additional benefit in ambulatory venous pressure,
when perforator interruption was performed after saphe-
nous vein ablation.
Percutaneous ablation of perforators. PAPS is a new
technique, and most publications had a small number of
patients with short follow-up, who were treated frequently
for mild disease (CEAP class C2-C3).
357 Most data pro-
vided are on safety and surrogate end points such as perfo-
rating vein occlusions but less so on clinical and functional
end points. A systematic review of five recently published
cohort studies and seven unpublished case series by
O’Donnell356 found a mean occlusion rate of 80% and a
mean follow-up of 2 months.
Ultrasonographically guided sclerotherapy is gaining
rapid acceptance because perforating veins can be accessed
easily with a small needle without much pain to the patient.
Masuda et al351 reported clinical results with ultrasono-
graphically guided sclerotherapy using morrhuate sodium
in 80 limbs with predominantly perforator incompetence
alone. The authors noticed a significant improvement in
VCSS, and ulcers rapidly healed in 86.5%, with a mean time
to heal of 36 days. The ulcer recurrence rate was 32% at a
mean of 20 months despite low compliance (15%) with
compression hose. New and recurrent perforators were
Guideline 13. Treatment of perforating veins
Guideline
No. 13. Treatment of perforating
13.1 We recommend against selective treatment of incom
patients with simple varicose veins (CEAP class C
13.2 We suggest treatment of “pathologic” perforating
with outward flow of 500-ms duration, with a
located beneath healed or open venous ulcer (cla
13.3 For treatment of “pathologic” perforating veins, w
endoscopic perforating vein surgery, ultrasonogr
sclerotherapy, or thermal ablations.identified in 33% of limbs, and ulcer recurrence was statis- rically associated with perforator recurrence as well as pres-
nce of postthrombotic syndrome.
Conclusions. Current data do not support adding
erforator ablation to ablation of the superficial system in
atients with simple varicose veins,361,362 and the Commit-
ee recommends against treatment of perforators in pa-
ients with CEAP class C2 disease (GRADE 1B). In patients
ith advanced CVI, current data provide moderate evi-
ence that large (3.5 mm), high-volume, incompetent
pathologic” perforators (reflux 500 ms), located in the
ffected area of the limb with outward flow on duplex
canning in patients with class C5 or C6 disease, can be
reated by experienced interventionists, unless the deep
eins are obstructed (GRADE 2B).22,56,87 Clinical data on
he efficacy of perforator ablations were obtained primarily
y using the SEPS procedure, but ultrasonographically
uided sclerotherapy or thermal ablations, when performed
ith similar low complication rates, can be suggested as
lternative therapy for perforator treatment (GRADE 2C).
elvic varicosity and pelvic congestion syndrome
Valvular incompetence and retrograde flow to the ovar-
an veins and/or the internal iliac vein and its tributaries
ay give rise to pelvic congestion syndrome and pelvic
aricosities, which may occur alone or together. Pelvic
ongestion syndrome is associated with symptoms of pelvic
ain or heaviness, dyspareunia, and dysuria. Varicose veins
n the vulvar and perivulvar area are most often secondary to
revious pregnancy and are often associated with perimen-
trual symptoms.
Evaluation. The appearance of varices in the region of
he pubis, labia, perineum, or buttocks suggests a pelvic
ource of reflux. Several noninvasive diagnostic tests are
vailable, including lower extremity, transabdominal, and
ransvaginal ultrasonography as well as CT and MR venog-
aphy.372 All have been reported to be useful in document-
ng pelvic venous reflux, although the selection of the most
ppropriate test largely depends on local institutional ex-
ertise. An ovarian vein diameter of6 mm on ultrasonog-
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for pelvic venous varices include four or more tortuous
parauterine veins, parauterine veins 4 mm in diameter,
and an ovarian vein diameter 8 mm.374
Retrograde ovarian and internal iliac venography is the
test of choice for the diagnosis of pelvic venous disorders,
although it is most often reserved for patients in whom
intervention is planned. Venographic criteria for pelvic
congestion syndrome include one or more of the following:
(1) an ovarian vein diameter of 6 mm, (2) contrast
retention for 20 seconds, (3) congestion of the pelvic
venous plexus and/or opacification of the ipsilateral (or
contralateral) internal iliac vein, or (4) filling of vulvovagi-
nal and thigh varicosities.375
Treatment. Various nonsurgical and surgical ap-
proaches are available to treat pelvic congestion syndrome.
Pharmacologic agents to suppress ovarian function, such as
medroxyprogesterone or gonadotropin-releasing hor-
mone, may offer short-term pain relief, but their long-term
effectiveness has not been proven. Surgical approaches,
including hysterectomy with unilateral or bilateral oopho-
rectomy and ovarian vein ligation and excision, with inter-
ruption of as many collateral veins as possible, have been
suggested for patients unresponsive to medical therapy.373
Percutaneous transcatheter embolization of refluxing
ovarian and internal iliac vein tributaries with coils, plugs,
or sclerotherapy, usually as combination treatment, has
become the standard approach for management of both
pelvic congestion syndrome and varices arising from a
pelvic source.
Results. Transcatheter therapy has been reported to
improve symptoms in 50% to 80% of patients. Chung and
Huh374 randomized 106 premenopausal women with
chronic pelvic pain unresponsive to medical treatment to
one of three treatment regimens: (1) ovarian vein emboli-
Guideline 14. Treatment of pelvic varicose veins
Guideline
No. 14. Treatment of pelvic varico
14.1 We recommend noninvasive imaging with transabd
ultrasonography, computed tomography or mag
in selected patients with symptoms of pelvic cong
symptomatic varices in the distribution of the pu
buttocks.
14.2 We recommend retrograde ovarian and internal ilia
with pelvic venous disease, confirmed or suspecte
studies, in whom intervention is planned.
14.3 We suggest treatment of pelvic congestion syndrom
coil embolization, plugs, or transcatheter sclerot
together.
14.4 If less invasive treatment is not available or has faile
ligation and excision of ovarian veins to treat reflzation, (2) laparoscopic hysterectomy, bilateral salpingo-ophorectomy, and hormone replacement, or (3) laparo-
copic hysterectomy and unilateral oophorectomy. Mean
ain scores as assessed on a 10-point visual analog scale
ere significantly improved among those undergoing ovar-
an vein embolization or bilateral oophorectomy, but not
mong those undergoing unilateral oophorectomy. Pain
eduction at 12 months was greatest in those undergoing
mbolotherapy.
ONCLUSIONS
The revolution in endovascular technology has trans-
ormed the evaluation and treatment of venous disease
uring the past decade. To keep up with the rapidly chang-
ng technology, in this document the Venous Guideline
ommittee of the SVS and the AVF provides evidence-
ased guidelines for the management of varicose veins and
ssociated CVDs in 2011. These guidelines are essential to
he clinical practice using evidence-based medicine and play
major role—but not the only role—in determining the
est care for patients with varicose veins and more advanced
orms of CVD. The scientific evidence presented in this
ocument must be combined with the physician’s clinical
xperience and the patient’s preference to select the best
iagnostic tests and the best treatment option for each
ndividual patient.
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